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Summary 
Infection is one of the major causes of increased morbidity and the escalating costs associated with 
orthopedic surgery. The areas that are infected are often difficult to reach and thus difficult to treat. 
In some surgeries antibiotic-loaded bone cements are used to control infection. 
Polymethylmethacrylate (PMMA) and calcium phosphate-based bone cements (CPC) are usually 
used as bone fillers. CPC are bioresorbable and biocompatible (unlike PMMA cements), but can 
only be used in non- or low-load bearing areas and are thus more applicable in cranio-and maxilla-
facial surgeries. Several in vitro and in vivo trials have been conducted on the incorporation of 
antibiotics and other therapeutic agents into CPC and the release of these agents. As with any solid 
matrix, release is defined by specific parameters, i.e. matrix porosity, solubility of the drug and 
interaction of the drug with the cement. 
The increase in antibiotic-resistant pathogens, mainly as a result of overuse of antibiotics, has a 
major impact on the choice of antibiotics that are used in the treatment of bacterial infections. The 
search for alternative antimicrobial compounds that are active against resistant pathogens, is thus of 
utmost importance. 
Antimicrobial peptides (bacteriocins) produced by lactic acid bacteria may pose a possible 
alternative to antibiotics. Some of these peptides are active against antibiotic-resistant pathogens. 
Bacteriocins are small cationic, hydrophobic, or amphiphilic peptides active against a narrow range 
of target organisms. Most of these peptides are active in the nanomolar range. It may then be 
advantageous to incorporate bacteriocins into CPC to evaluate if they may be used as an alternative 
to antibiotics. 
The aim of the project was to evaluate if bacteriocins could be successfully incorporated into self 
seting brushite bone cement and remain effective in vivo without altering basic cement 
characteristics. Incorporation of bacteriocins into CPC is a novel concept. The low setting 
temperature and pH of CPC renders it the ideal matrix for incorporation of antimicrobial peptides. 
In this study, peptide ST4SA, a class IIa broad-spectrum bacteriocin, has been incorporated into 
brushite bone cement and characterized in vitro. Incorporation of the peptide did not have a 
significant effect on the crystal entanglement or setting reaction of the cement. Peptide ST4SA was 
rapidly released and inhibited the growth of the target strain effectively. In another experiment, 
peptide ST4SA was suspended in poly (lactide-co-glycolide) and electrosprayed to form micro 
particles that were entrapped in brushite cement. Association of the peptide with microparticles 
resulted in a delayed release from the cement, followed by a constant release. 
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Nisin F, a class Ia bacteriocin was also incorporated into brushite cement and its activity studied in 
vitro and in vivo. Similar results were observed in vitro as recorded with peptide ST4SA 
incorporated into brushite cement. Small cylinders of brushite cement loaded with nisin F were 
implanted into subcutaneous pockets in mice and each pocket infected with a bioluminescent strain 
of Staphylococcus aureus (Xen 36). Nisin F in the bone cement prevented the growth of S. aureus 
in the wound and controlled infection. 
With this study we have shown that antimicrobial peptides that differ in structure (classes I and II) 
could be incorporated into bone cement and control the growth of S. aureus in vivo and in vitro.  
The mode of action of these peptides differs from antibiotics in that they form a permanent pore in 
the cell membrane of the target organism.  This minimizes the chance of a strain becoming resistant 
to the peptide.  Incorporation of antimicrobial peptides into bone cement may be a possible 
alternative to antibiotics in the control of bacterial infections associated with implants.   
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Opsomming 
Infeksie is een van die grootste bydraende faktore tot sterftes en verhoogde kostes in ortopediese 
chirurgie. Geinfekteerde areas is dikwels moeilik bereikbaar en dus ook moeilik om te behandel. In 
sommige operasies word antibiotika-gelaaide beensement gebruik om infeksie te beheer. 
Polymetielmetakrilaat (PMMS) en kalsium fosfaat gebaseerde beensement (KFS) word gebruik as 
been vullers. KFS is bioverenigbaar en bio-absorberend (in teenstelling met PMMS), maar kan 
slegs in geen- of liggewig-draende areas gebruik word en is dus van groter toepassing in skedel-, 
kaak- gesig- en mondchirurgie. Verskeie in vitro en in vivo toetse is al gedoen op die inkorporering 
van antibiotika en ander terapeutiese middels in KFS en die vrystelling daarvan uit die matriks. 
Soos met enige soliede matriks is vrylating van die geïnkorporeerde bestanddeel afhanklik van 
sekere parameters, onder andere porositeit, oplosbaarheid van die middel, en die interaksie van die 
middel met beensement. 
Die toename in antibiotika-weerstandbiedende patogene plaas geweldige druk op die keuse van 
antibiotika wat gebruik word in die beheer van bakteriese infeksie. Die soeke na alternatiewe 
antimikrobiese middels aktief teen bestande patogene is dus van kardinale belang.  
Antimikrobiese peptiede (bakteriosiene) gepproduseer deur melksuur bakterieë mag dalk ŉ 
alternatief tot antibiotika wees. Sommige van hierdie peptiede is aktief teen verskeie 
weerstandbiedende patogene. Bakteriosiene is kationiese, hidrofobiese of amfifiliese peptiede wat 
naverwante bakterieë inhibeer of doodmaak. Die meeste van hierdie peptiede is aktief op nanoskaal 
vlak. Dit mag dalk dus voordelig wees om bakteriosiene in been sement te evalueer as moontlike 
alternatiewe tot antibiotika. 
Die doel van die proejek was om te evaleer of bakteriosiene suksesfol in “brushite” sement 
geinkorporeer kan word en steeds effektief in vivo bly sonder om die basiese einskappe van die 
sement te verander. Inkorporasie van bakteriosiene in KFS is ŉ nuwe konsep. Die lae 
stollingstemperatuur en pH van KFS maak dit moontlik om bakteriosiene daarin te inkorporeer. In 
hierdie studie is peptied ST4SA, ŉ klas IIa wye-spektrum bakteriosien, in “brushite” sement 
geïnkorporeer en in vitro bestudeer. Die toevoeging van die peptied het nie ŉ beduidende effek op 
die stolreaksie of kristal verstrikking van die sement gehad nie. Peptied ST4SA is effektief 
vrygelaat en het die groei van die teikenorganisme suksesvol onderdruk. In „n ander eksperiment is 
peptied ST4SA in poli (D,L-laktied-ko-glikolied) gesuspendeer en met behulp van elektrosproeiing 
tot mikropartikels omvorm en is in “brushite” sement geïnkorporeer. Assosiasie van die peptied met 
mikropartikels het die inisiële vrylating van die peptied vertraag, gevolg deur „n konstante 
vrylating.  
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Nisien F, ŉ klas Ia lantibiotikum, is ook in “brushite” sement geïnkorporeer en die aktiwiteit 
daarvan in vitro en in vivo bestudeer. Die in vitro eienskappe is soortgelyk aan die eienskappe wat 
vir peptied ST4SA-gelaaide sement waargeneem is. Klein stafies “brushite” sement, waarin nisien F 
geïnkoproreer is, is in onderhuidse sakkies in muise geplaas en die area met ŉ bio-liggewende 
bakterie (S. aureus Xen 36) geïnfekteer. Nisien F in die beensement het die groei van S. aureus in 
die wond onderdruk en infeksie beheer.  
Met hierdie studie het ons bewys dat bakteriosiene wat struktureel van mekaar verskil (klasse I en 
II) in beensement geïnkorporeer kan word en die groei van S. aureus in vitro en in vivo kon beheer. 
Die wyse waarop hierdie peptiede die groei van sensitiewe organismes inhibeer verskil van dié van 
antibiotika deurdat dit porieë in die selmembraan vorm. Die moontlikheid dat organismes 
weerstandbiedend raak tot die peptied is dus heelwat skraler. Die insluit van antimikrobiese 
peptiede in beensement mag dalk ŉ alternatief tot antibiotika wees in die voorkoming van bakteriële 
infeksie geassosieer met ortopediese chirurgie.   
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Preface 
This thesis is presented as a compilation of manuscripts. Each chapter is introduced separately and 
is written according to the style of the respective journal. One article has been published from the 
current research and two manuscripts have been submitted for publication. The addendums contain 
additional information not presented in the main chapters. All other sections and chapters are 
written according to the instructions for Journal of Applied Microbiology. 
Chapter 2.1, “Calcium orthophosphate-based bone cements (CPCs): Applications, antibiotic release 
and alternatives to antibiotics” has been submitted to Journal of Biomaterials and Biomechanics. 
Chapter 3, “Release of Enterococcus mundtii bacteriocin ST4SA from self-setting brushite bone 
cement” has been published in Probiotics and Antimicrobial Proteins, vol. 3, pp. 119-124 (2011).  
Chapter 5, “Nisin F-loaded brushite bone cement prevented the growth of Staphylococcus aureus in 
vivo” has been previsionally accepted for publication in Journal of Applied Microbiology 
(November 2011). 
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Introduction 
Infections associated with orthopedic surgery are a major cause of morbidity and cost (Cosgrove 
and Carmeli 2003; Zimmerli 2006). Bone as a solid matrix does not expand and contract as 
readily as other tissue, resulting in antibiotics being less effective when taken intravenously or 
orally (Frommelt 2006). Antibiotic-loaded bone cements have been used as a prophylactic 
measure to prevent infection (Jiranek et al. 2006). Polymethylmethacrylate (PMMA) cement is 
the standard mixture used in most orthopedic surgeries. The polymer is non-biodegradable, i.e. it 
cannot be resorbed by the body under natural conditions (van Landuyt et al. 1999; Van de Belt et 
al. 2001). Calcium phosphate-based bone cements (CPC) have also been extensively 
investigated, due to their bioresorbable and biocompatible properties. These cements have lower 
mechanical strength and are usually only used in non- or low-load bearing areas, and are thus 
more applicable in cranio- and maxillo-facial surgeries (Ambard and Mueninghoff 2006). CPC 
have shown promise clinically and antibiotic-loaded CPC have been investigated extensively in 
vitro and in vivo (Miyamoto et al. 1995; Ohura et al. 1996; Kurashina et al. 1997; Otsuka et al. 
1997; Petruzzelli and Stankiewicz 2002; Kasperk et al. 2005; Ruhe et al. 2005; Schnieders et al. 
2006; Ginebra et al. 2006; Alkhraisat et al. 2010; Fullana et al. 2010; Neovius and Engstrand 
2010). The abuse of antibiotics over the past few decades has resulted in an increase in 
antibiotic-resistant pathogens (Neu 1992). Infection with an antibiotic-resistant pathogen is one 
of the major concerns in hospitals across the world. The low yield in novel and effective 
antibiotic discovery has limited the last defence antibiotics to only a few (Fischbach and Walsh 
2009). The search for alternatives to antibiotics is therefore important if antibiotic-resistant 
pathogens are to be kept under control (Joerger 2003).  
Bacteriocins produced by Gram-positive bacteria may provide a possible alternative to 
antibiotics. Bacteriocins have been around as long as antibiotics, but have not yet been 
established as a viable alternative (Nes 2011). Bacteriocins are antimicrobial peptides with 
activity against a narrow range of bacteria, unlike most antibiotics that have a broad range of 
activity. The advantage of bacteriocins over antibiotics is that they are active in nanomolar 
concentrations, and usually only against specific species (Morgan et al. 2005; Nissen-Meyer et 
al. 2009). Bacteriocins from lactic acid bacteria (LAB) have received the most attention, mainly 
due to importance of these bacteria in food fermentations. Bacteriocins are divided into three 
main groups, i.e. the post-transcriptionally modified heat-stable lantibiotics (class I) and the non-
modified heat-stable bacteriocins (class II). The main classes are further subdivided into 
subclasses. The third group (formerly class III) consists of heat-liable bacteriolysins (Rea et al. 
2011). Bacteriocins have shown antimicrobial activity against antibiotic-resistant pathogens such 
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as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci (Piper et al. 
2010). The spectrum of antiomicrobial activity of bacteriocins may be broadened when used in 
combination with other therapeutic agents (Ghiselli et al. 2004). The possible use of bacteriocins 
in association with prosthetic implants and other medical devices have been investigated in vitro 
and in vivo (Bower et al. 2002; Ghiselli et al. 2004; Van Staden et al. 2011). These studies 
revealed promising results and are paving the road to the development of alternative 
antimicrobial therapy. 
This study investigated the possibility to incorporate peptide ST4SA, a class II bacteriocin 
produced by Enterococcus mundtii ST4SA, and nisin F, a class I bacteriocin produced by 
Lactococcus lactis subsp. lactis F10 into CPC. The structural, chemical and antimicrobial 
properties of CPC, impregnated with peptide ST4SA, nisin F and PLGA-associated peptide 
ST4SA, have been studied.  The in vivo activity of nisin F-loaded brushite cement was studied in 
mice that have been infected with S. aureus Xen 36.  
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Abstract: Calcium orthophosphate bone cements (CPCs) are widely used in orthopedic surgery. 
Implants are highly susceptible to infection and often lead to the formation of microbial biofilms. 
Antibiotics are often incorporated into bone cement. The increase in number of microorganisms 
acquiring or developing resistance to antibiotics, such as methicillin resistant Staphylococcus 
aureus (MRSA) and vancomycin resistant enterococci (VRE), is a major concern. Bacteriocins 
(antimicrobial peptides) offer an alternative to antibiotics. Their mode of activity involves 
permanent destabilization of the plasma membrane of target cells, rendering little chance of 
developing resistance. A number of broad-spectrum bacteriocins produced by lactic acid 
bacteria and Bacillus spp. have recently been described. In this review the major characteristics 
of calcium phosphate bone cements, prosthetic joint associated infections and treatment of these 
infections is discussed. The role of antimicrobial agents in CPCs is discussed and the possibility 
of incorporating bacteriocins in prosthetic devices is investigated. 
KEY WORDS: Calcium phosphate bone cement; prosthetic joint infection; nano/microparticles; 
bacteriocins 
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INTRODUCTION 
Calcium orthophosphate based cements (CPCs) are widely used in orthopedic and maxillofacial 
surgery and numerous papers have been published on the in vitro/in vivo properties of different 
CPC formulations (Table I) 
(1-11)
. CPCs have excellent osteoconductive properties, i.e. low 
interference with bone function, are replaced by new bone tissue, are easily moulded and set in 
situ 
(5-9)
. CPCs made from brushite and hydroxyapatite has the added advantage of being 
bioresorbable, which excludes the need for autografts and allografts
(9)
. 
Implants and bone replacement materials provide an ideal environment for infection and 
microbial biofilm formation 
(12)
. Infections may lead to serious complications, often requiring 
debridement or complete removal of the prosthesis 
(13-15)
. Infection is normally prevented by 
prophylactic treatment with antibiotics. However, blood flow surrounding areas of implants is 
usually poor, which results in little success achieved with antibiotics administered intravenously 
or orally 
(12)
. Non-resorbable polymers such as poly-methylmethacrylate spheres (PMMA), 
combined with antibiotics have been used with some success. However, PMMA implants have to 
be removed, thus increasing the chance of contracting secondary infection 
(9)
. Unlike PMMA, 
CPC implants can be resorbed by osteoclasts and do not need to be removed. A number of 
papers have been published describing the incorporation and release of antibiotics into CPCs 
(16-
21)
. 
This review discusses the major characteristics of CPCs and problems encountered with 
orthopedic and maxillofacial infections. The role of antimicrobial agents in CPCs is discussed 
and the idea of including bacteriocins (antibacterial peptides) in bone cements is investigated. 
Characteristics of CPCs 
Several compositions of CPCs are used in orthopedic and maxillofacial constructions. CPCs are 
biocompatible, osteogenic and osteoconductive, rendering them the ideal substitute for bone  
(4, 
21-28)
. CPCs are produced by mixing a reactive calcium phosphate with a liquid solvent to 
produce a rapidly setting paste 
(21)
. The aqueous phase allows for the dissolution of the initial 
calcium orthophosphates, supplying calcium and orthophosphate ions to the solution. The ions 
interact and precipitate to form either the end products or precursor phases 
(29, 30)
.  The chemical 
reactions that take place during setting of CPCs depends on their composition, however there are 
only two chemical types of setting reactions. Reactions may be either acid-base (two-component 
cements) reactions (interaction) or the transformation of a metastable phase into a more stable 
phase (one-component cements). 
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The first chemical type forms due to an acid-base interaction between a relatively neutral/basic 
calcium orthophosphate and an acidic calcium orthophosphate 
(29, 30)
. In the reaction below (eq. 
1) tetracalcium phosphate (basic) reacts with anhydrous dicalcium phosphate (neutral) to 
produce a slightly basic hydroxyapatite. 
2Ca2 (PO4)2O + 2CaHPO4  Ca10(PO4)6(OH)2   (1) 
In the formulation used by Lemaitre and co-workers 
(31)
, -tricalcium phosphate (close to pH 
7.0) reacts with acidic monohydrate monocalcium phosphate (eq. 2) to form slightly acidic 
dicalcium phosphate dihydrate (DCPD), also known as brushite. 
-Ca3(PO4)2 + Ca(H2PO4)2 
. 
H2O + 7 H2O  4CaHPO4 
. 
2H2O (2) 
The second chemical type is the transformation (hydrolysis) of a calcium orthophosphate from a 
metastable phase into a more stable phase 
(21, 30)
. After mixing, the calcium phosphate (CaP) 
precipitates and forms crystals with specific mechanical properties 
(29)
. Only one calcium 
orthophosphate takes part in the reaction, producing a stable calcium:phosphate ionic ratio 
(30)
. A 
typical example of such a reaction is shown in eq. 3, where / -tricalcium phosphate, 
nanocrystalline TTCP or ACP dissolved in water forms calcium-deficient hydroxyapatite 
(CDHA) crystals 
(29, 30)
. A single-phase cement powder, consisting of K- and Na-containing 
CDHA, has been proposed by Tas and Aldinger 
(32)
. 
3 ( -/ -)Ca3(PO4)2 + H2O  Ca9(HPO4)( PO4)5(OH)  (3) 
Apatite cements 
Apatite cements are usually highly viscous and easily moldable and set at or above physiological 
pH, depending on the solvent 
(10, 29)
. Water is not a reactant in the setting reaction of most apatite 
cements and only allows for the dissolution of the initial calcium phosphates 
(30)
. Therefore, the 
amount of water needed in apatite cements is small. In brushite cements water always takes part 
in the transformation reaction and is required for DCPD formation. Brushite cements are 
therefore known as hydraulic cements, whereas apatite cements usually do not carry this label 
(30, 
34)
. The setting reaction results in poorly crystalline hydroxyapatite (pHA) or CDHA, with 
possible traces of non-reacting starting material 
(20, 23-29)
. If carbonates are present in the initial 
mixture, non-stoichiometric carbonate apatite (Ca8.8(HPO4)0.7(PO4)4.5 CO3)0.7 (OH)1.3) may form 
as final product 
(35-36)
. CDHA and carbonate apatite have a low crystallinity, similar to that found 
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in biological apatite (bones and teeth). CDHA has good in vivo resorption characteristics 
(23, 37)
 
and is ideal to use as bone replacement material. 
The setting rate of apatite cements is longer compared to brushite cements and may thus cause 
complications in operations 
(10, 29, 38)
. To decrease the setting reaction, phosphoric acid, MCPM, 
soluble orthophosphates or precipitated HA particles may be added 
(10-11, 20, 27, 37)
. These additives 
reduce the setting time to 10-15 min, which is acceptable in a clinical environment with an ideal 
setting time; shorter than 15 min 
(30)
. Setting time is also influenced by particle size and volume 
of the solvent 
(10, 38)
. 
Mixing with water dissolves the initial calcium orthophosphates and crystals form 
(23)
. 
Mechanical strength of apatite cements is influenced by particle (powder) size, powder to liquid 
ratio and type of solvent used 
(33, 39)
. Porosity plays a major role in mechanical properties. A 
higher powder to liquid ratio decreases porosity, which results in an increase in mechanical 
strength 
(10, 29)
. However, decreased porosity may result in decreased osteoconductivity. High 
compressive strength does not, however, mean the cement is capable of withstanding shear 
forces in vivo. Tensile strength is an important parameter in developing a formulation for in vivo 
applications 
(29, 40)
. The compressive- and tensile-strengths of most CPCs are diverse, ranging 
from 10-100 MPa for compressive strength and 1-10 MPa for tensile strength, depending on the 
formulation 
(29)
. Apatite cements usually fall in the higher end of this scale, but are used in 
combination with metal implants or in low-load bearing areas 
(10-11)
. 
Apatite cements compare well with biological apatite, rendering them biocompatible 
(26, 30, 41)
. 
The forces linking the crystals are weak, which allow them to easily detach in vivo and be 
ingested by osteoclasts and macrophages. This is followed by replacement of bone by osteoblasts 
(8, 27, 42)
. The biocompatibility and resorbability of apatite cements have been illustrated with in 
vivo experiments 
(2, 20, 26-27, 41)
. 
Brushite cements 
Unlike most apatite cements, brushite cements are hydraulic, i.e. water always participates in the 
chemical transformations involved in DCPD formation 
(30)
. The setting of brushite cements is 
based on acid base reaction/interaction (eq. 2) and precipitates to DCPD (mineral; brushite) at 
pH<6.0 
(11, 43)
, resulting in an acidic paste. As with apatite cements, several formulations are used 
for brushite cements, including βTCP + MCPM (eq. 2), βTCP + H3PO4, nanocrystalline HA + 
H3PO4, and tetracalcium phosphate + MCPM 
(43-44)
. Unlike apatite cements, brushite cements 
may start out as a liquid but rapidly sets into hard cement 
(29, 45-46)
. Setting times may be as short 
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as 30-60 seconds, necessitating the use of retardants such as trisodium citrate, citric acid or 
pyrophosphates. These additives inhibit the formation of DCPD crystals, which may have an 
influence on mechanical properties 
(11, 45-46)
. Some additives increase the setting time of brushite 
from 30-60 sec to 5-10 min 
(11, 47)
. 
Brushite cements are biocompatible and bioresorbable, and due to higher solubility of DCPD 
compared to CDHA, they are degraded faster in vivo compared to apatite cements 
(48)
. The fast 
degradation results in a loss of mechanical strength, but as the resorbed cement is replaced by 
bone cells, the mechanical strength of the defected site increases 
(7, 49-50)
. Low mechanical 
strength (ranging from 10 MPa to 60 MPa) and high degradation of brushite cements make them 
slightly inferior to apatite cements 
(51)
. The high degradation of brushite may result in the cement 
being resorbed faster than bone replacement takes place, resulting in the formation of immature 
bone or gaps between cement and bone 
(25, 48)
. Brushite cements are not only resorbed by 
osteoclasts, but also by dissolution, resulting in high degradation rates 
(29)
. Addition of a bone 
anchor, such as βTCP granules, promotes formation of mature bone (7, 29, 52-53). Incorporation of 
growth factors into the cement increases tissue response (i.e. bone formation) to brushite cement 
(25)
. The high resorption properties of brushite can however provide an edge over the stable 
apatite cements with longer resorption characteristics. 
Inflammation caused by brushite cements may be due to the release of orthophosphoric acid 
when DCPD is partially converted to CDHA 
(54, 55)
. This can be prevented by the addition of 
magnesium ions (in vitro), or by the implantation of preset cements 
(56, 57)
.  
CPCs in orthopedic surgery 
The use of CPCs in orthopedic surgery is limited due to their mechanical prosperities. Positive 
results have been reported with the use of CPCs in the treatment of fractures, with decrease in 
patient pain and a reduced risk of losing fracture reduction when compared with autogenous 
bone graft 
(58-60)
. Cement augmentation after hardware removal have positive results, including 
increase failure strength which reduces the chances of refracture and allows for earlier weight 
bearing 
(61)
. CPCs can also be used to coat prosthetic implants for improved fixation. 
The use of CPCs has also been investigated for use in vertebroplasty and kyphoplasty 
(30)
. Using 
a canine model, Turner and co-workers showed that CPCs are viable alternatives to PMMA 
cements in the treatment of large vertebral defects 
(62)
. If the vertebroplasty procedures are done 
correctly with the appropriated amount of CPC (correct powder to liquid ratio), positive results 
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are obtained without complications 
(62-64)
. CPCs have been successfully used in kyphoplasty 
resulting in increased vertebral height, reduced pain and increased patient mobility 
(65)
. 
Infection 
Infections associated with orthopedic surgery are rare 
(13-14)
, but difficult to diagnose and treat. 
Orthopedic implants are highly susceptible to infection and provide a prime spot for biofilm 
producing bacteria to flourish 
(12, 66-67)
. Improvements in health care have resulted in increased 
life expectancy, which in turn means the number of patients that require orthopedic implant 
surgery are on the increase, combined with an increase in the risk of acquiring an infection 
(68)
. 
Risk of contracting an infection is also associated with nutritional status, history of pre-existing 
joint disease (e.g. arthritis), diabetes, obesity 
(69-71)
, prior infection of native bone, surgical site 
infection (unrelated to prosthesis) and HIV infection 
(66, 68, 71)
. Hematogenous infection is spurred 
by bacteraemia, caused by skin, respiratory tract, dental and other systemic infections 
(72-73)
. 
Microorganisms infect implants during surgery, through hematogeneous seeding caused by 
unrelated bacteraemia, or direct spreading from neighbouring lesions. Streptococci, 
Staphylococcus aureus and Gram-negative bacilli are usually associated with prosthetic and bone 
infections 
(69, 74-75)
. 
CPCs in craniofacial and maxillofacial surgery 
The use of CPCs in craniofacial (CF) and maxillofacial (MF) surgeries provides various 
advantages including the reduced use of autologous grafts and alloplastic implants 
(30)
. The low 
mechanical stress associated with these areas means low mechanical properties of CPCs do not 
play such a huge role. The ability to mould the CPC paste in situ provides an additional clinical 
advantage 
(76)
. Several authors have shown high biocompatibility and bioresorbability of CPCs, 
with little or no occurrence of inflammation 
(2, 6-7, 26-27, 41, 48, 57)
. Implant stability is an important 
factor in CF and MF surgeries. Membranes and meshes are frequently used and it is important 
that they do not interfere with the implant. Losee and co-workers 
(77)
 showed that a PLA mesh 
did not interfere with the osteoconductivity, remodelling capacity and biocompatibility of 
cement. Tamimi and co-workers 
(78)
 have also showed that it is possible to obtain stable CPC 
implantation without reinforcement. Friedmann and co-workers 
(79)
 used hydroxyapatite cement 
for the reconstruction of frontal sinus and the frontofacial skeleton of 38 patients. They reported 
an 82% overall success rate for the reconstructions and suggested it‟s superiority over acrylic 
implants. Other studies have also reported high success rates when using CPCs in CF and MF 
surgeries 
(80-81)
. 
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Infection 
Infection is the most common complication in CF and MF surgery and results in high morbidity 
(82)
. Infection may result due to secondary surgery, resulting in extended hospital stay, additional 
procedures as well as increase chances of deformity 
(83-84)
. The close proximity of these surgical 
sites to areas with a high bacterial flora (nasal and oral cavities) may also result in increase 
contamination 
(83)
. 
Fialkov and co-workers 
(83)
 reported an infection rate of 8% during 349 CF surgeries. This is 
higher than for other orthopedic surgeries and may be due to contamination with nasal and/or 
nasal flora. Wong and co-workers 
(85)
 reported on infection rates of secondary CF surgeries 
involving hydroxyapatite cements. Of the 17 patients studied, 10 presented with infection, 9 
patients required debridement, followed by delayed reconstruction.  Their study shows a high 
rate of infection with Norian cement and is not the first report of mixed results using this cement 
(86)
. Fearon and co-workers 
(82)
 reported a lower infection rate (2.5%) in 567 patients undergoing 
intracranial surgery, with 85% of infection occurring after secondary operations.  
Antibiotic-loaded CPCs 
Characteristics such as bio activity, bioresorbability, injectability and rapid in situ setting render 
CPCs attractive drug delivery vectors. Furthermore, CPCs set at low-temperatures which allow 
the incorporation of heat liable drugs or proteins 
(29)
. Prophylactic antibiotics are usually taken 
orally or intravenously which limits their access to the effected bone site. Bone is a solid matrix 
and cannot expand. Thus, inflammation causes a reduction in blood flow, which restricts contact 
between the pathogen and the antibiotic 
(12, 87)
. CPCs can access inaccessible bone sites and 
deliver drugs in a high concentration without being toxic to the rest of the body. Localized 
treatment is advantageous in the treatment of skeletal disorders (osteoporosis and osteoarthritis) 
and infections, which usually require long and painful treatments. Other drugs or proteins, 
including anti-cancer and anti-inflammatory agents, can also be incorporated into CPCs 
(9, 37, 88)
. 
The advantage CPCs has over ceramics is that drugs can be added to any one of the two phases, 
whereas in ceramics the drugs have to be impregnated 
(9)
. Several factors influence release of 
antimicrobial agents from CPCs. Parameters such as cement chemistry, drug cement interaction, 
cement porosity as well as use of polymeric drug delivery systems, may influence drug release. 
Several studies have been performed to determine the drug loading capacity of CPCs (Table I). 
Bohner and co-workers 
(43)
 investigated the properties of gentamicin-loaded brushite cement. 
The antibiotic did not affect the physiochemical properties of CPCs and was released in an active 
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form. Compared to gentamicin-loaded PMMA beads 
(47)
, which are not resorbable, have very 
slow release rates and have to be surgically removed after a few months, gentamicin loaded 
brushite cement has a clear advantage. Young and co-workers 
(18)
 studied chlorhexidine (non-
antibiotic) loaded CPCs. The results obtained were similar to the gentamicin loaded cement. 
Both cements followed Fickian diffusion, i.e. a high initial burst release, followed by a plateau 
until most of the drug is released. Both authors concluded that the released drug was suitable for 
the treatment of initial infection and that the incorporated drugs had no negative effects on the 
physiochemical properties of the cements.  Hofmann and co-workers 
(38)
 experimented with the 
porosity of cement.  The authors reported an almost linear drug release over 350 h. However, 
reducing the porosity of the cement has a negative effect on osteoconductive properties 
(89)
. 
For CPCs from which antibiotics are rapidly released a polymeric drug delivery system may be 
incorporated. The use of nanotechnology to control drug release from biodegradable nanofibers 
and nano- or microparticles has been extensively studied over the past few years 
(90-94)
. The 
release rate depends on several factors, including the interaction between the drug and polymer 
(95)
. A hydrophobic, e.g. poly (L-lactic acid) (PLLA) or polycaprolactone (PCL) polymer 
provides a slow release and, in some cases, only degrades over several months. In contrast to 
this, a hydrophilic polymer such as poly (ethylene oxide) (PEO), releases the antibiotic at a rapid 
rate 
(93)
. Co-polymers such as poly (lactide-co-glycolic acid) (PLGA) or blends of structurally 
different polymers (block polymers), have a slower release rate and offer an alternative to 
treatment over an extended period 
(93)
. It is thus important to select a polymer with the correct 
release kinetics. 
Gentamicin incorporated as microparticles into CPCs is slowly released 
(19)
. Gentamicin 
incorporated into PLGA resulted in a linear release profile that lasted for 100 days. The 
minimum inhibitory concentration (MIC) of the antibiotic was released at each of the time points 
monitored. Bohner and co-workers 
(43)
 experimented with a double-delivery system, i.e. 
microparticles were first released from the CPCs, followed by release of the antibiotic from the 
microparticles. The authors claim to have achieved a more controlled release of the antibiotic, 
illustrating the effectiveness of using a double-delivery system. A study by Takechi and co-
workers 
(96)
 showed the incorporation of flomoxef sodium into an anti washout apatite cement 
(containing chitosan). They reported a rapid release for the first 24 h followed by a less 
pronounced release for up to 72h, with a total of 49% release seen in the highest loaded samples. 
They also showed that it is possible to decrease the initial release as well as increase the amount 
of antibiotic released with the addition of chitosan to the cement mixture.  
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Stellmann and co-workers 
(2)
 reported a decrease S. aureus infection in a rabbit femur model 
when using an antimicrobial peptide (hLF1-11) loaded cement. They however also showed that 
using a gentamicin loaded cement resulted in a larger number of sterile femurs. Another in vivo 
study by Hamanishi and co-workers 
(20)
 investigated the release of vancomycin from cement 
when implanted in tibial condyles of rabbits. They found that the concentration of vancomycin in 
the bone marrow was above the MIC 3 weeks after implantation. High concentrations of the 
antibiotic did seem to interfere with initial bone ingrowth, resulting in fibrous tissue between 
cement and new bone. 
CPCs can also be used to deliver anti-inflammatory agents, anti-cancer drugs, proteins and 
growth factors.  
Although the incorporation of antibiotic-loaded cement with prosthesis is common practice, only 
a few in vivo studies and clinical trials have been done to evaluate its effectiveness. It cannot be 
assumed that the same release kinetics observed in vitro will be recorded in more complex in 
vivo circumstances. 
Alternatives to antibiotics: Bacteriocins 
The increase in number of microorganisms acquiring or developing resistance to antibiotics is a 
major concern 
(97)
. Pulido and co-workers 
(13)
 identified 63 patients out of 9245 with prosthetic 
joint infections. In 91% of the cases the causative organism could be identified, of which 30% 
were resistant to methicillin. Incorporation of antibiotics in bone cement can also increases the 
potential for antibiotic resistance, as illustrated by Thornes and co-workers
 (97)
. In this study, a 
higher percentage (78%) of antibiotic-resistant Staphylococcus epidermis has been recorded in 
gentamicin-loaded cement. Alternatives to antibiotics are therefore needed to reduce the 
emergence of antibiotic resistant pathogens 
(98)
. 
Bacteriocins (antimicrobial peptides) produced by lactic acid bacteria are possible alternatives to 
antibiotics. They are small, ribosomally synthesized cationic, hydrophobic and amphiphilic 
peptides composed of 20-60 amino acid residues and are divided into three classes 
(99-100)
. 
Bacteriocins show antimicrobial activity against closely related species and in several cases 
against antibiotic resistant microorganisms such as MRSA (methicillin resistant Staphylococcus 
aureus) and VRE (vancomycin resistant enterococci) 
(101-105)
. Nisin F, produced by Lactococcus 
lactis F10, inhibits growth of clinical S. aureus strains in vitro and in vivo. An in vivo study by 
Brand and co-workers. 
(106)
 showed that Nisin F10 was able to control S. aureus Xen 36 infection 
for at least 15 min. The short activity is most likely due to degradation by proteolytic enzymes. 
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However, Nisin F has been indicated as the most promising natural nisin variant for clinical 
applications 
(94)
. Mersacidin produced by Bacillus sp. HIL Y-85, has also been shown to 
eradicate MRSA in vitro and shows potential for clinical application 
(105)
. 
The main drawback of using bacteriocins is their instability in vivo 
(106)
. Instability may be 
overcome by encapsulating the bacteriocins with biocompatible polymers. Salmaso and co-
workers 
(107)
 showed that poly-L-lactide nanoparticles containing nisin had prolonged 
antimicrobial activity (in vitro) compared to nisin not encapsulated. In addition to stability, 
polymeric delivery systems also provide controlled release 
(107)
. Bacteriocins can be used in 
conjunction with antibiotics to reduce resistance and increase antimicrobial activity. 
Incorporation of bacteriocins into bone cements, directly or using a polymer based system, can 
provide a solution to the increase in antibiotic resistance and may thus increase the effectiveness 
of antibiotics. 
Conclusion 
Incorporation of growth factors, proteins, and anti-cancer and anti-inflammatory agents in CPCs 
is now common practice. Incorporation of antibiotics into CPCs proofed effective. However, 
special care has to be taken to avoid an increase in antibiotic resistance. The use of bacteriocins 
in combination with, or as an alternative to, antibiotics may be used in the fight against antibiotic 
resistant pathogens. Polymer nanotechnology shows great potential in controlling the release of 
drugs from cements and as a method to protect drugs against enzymatic degradation. The 
inclusion of antimicrobial peptides in nano- and microparticles incorporated into bone cements 
has to be investigated. This also requires more research on drug incorporation and drug release 
kinetics. 
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TABLE I - EXAMPLES OF CALCIUM PHOSPHATE CEMENT MIXTURES AND 
INCORPORATED THERAPEUTIC AGENTS (WHERE INDICATED)  
Cement formulation Study Incorporated Substance type 
TTCP
a
 , DCP
b 
In vivo hLF1-11 peptide Antimicrobial peptide 
TTCP, DCPD
c
 (apatite cement) In vitro/ 
In vivo 
Vancomycin Antibiotic 
β-TCPd, MCPMd (brushite cement) In vitro RANKLh Bioactive molecule 
(protein) 
α-TCPd, DCPAf, CaCO3, HA In vivo Rh-BMP-2
i 
Growth factor (protein) 
Sr-β-TCP, MCPM In vitro Doxycycline Antibiotic 
β-TCP, MCPM (brushite cement) In vitro Gentamicin Antibiotic 
β-TCP, MCPM, chitosan (brushite 
cement) 
In vivo VEGF
j
, PDGF
k 
Growth factors (protein) 
TTCP, DCPA In vitro N/A N/A 
Not specified In vivo Gentamicin Antibiotic 
TTCP, DCPD In vitro Mercatopurine Anticancer drug 
TTCP, DCPD, HA
g 
In vitro/ 
In vivo 
Indomethacin, Anti-inflammatory agent 
TTCP, DCPA In vitro N/A N/A 
β-TCP, MCPM (brushite cement) 
 
In vitro Vancomycin & 
ciprofloxacin 
Antibiotics 
β-TCP, MCPM (brushite cement) 
 
In vitro Chlorohexidine Antimicrobial agent 
TTCP, DCPA
c
, Chitosan In vitro Flomoxef 
sodium 
Antibiotic 
α-TCP, TTCP, DCPD, PLLAl In vivo Albekacin 
sulfate 
Antibiotic 
a 
Tetratricalcium phosphate; 
b 
Dicalcium phosphate; 
c 
Dicalcium phosphate anhydrous/dehydrate; 
d
 α/β-tricalcium 
phosphate; 
e
 Monocalcium phosphate monohydrate; 
f 
Dicalcium phosphate anhydrous; 
g
 Hydroxyapatite; 
h
 
Receptor activator for nuclear factor κ B ligand; i Recombinant human bone morphogenetic protein-2; j Vascular 
endothelial growth factor; 
k
 Platelet derived growth factor; 
l 
Poly-L-lactic acid. 
[2, 5, 10, 18, 20, 25, 37, 38, 43, 88, 96-97, 108-111] 
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Introduction 
Increase in multi-drug resistant pathogens (MDRP) has substantial social and economic 
implications (Lister 2002; Cosgrove and Carmeli 2003). The frequent use of antibiotics has 
accelerated the incidence of resistance among pathogens. In 1941 almost all strains of 
Staphylococcus aureus were susceptible to penicillin G. However, by 1944 strains of S. aureus 
capable of producing β-lactamase to inactivate penicillin G have been reported (Neu 1992). The 
excessive use of ceftazidime is another example of the association between antibiotic misuse and 
spread of microbial resistance (Rice et al. 1990).  A decrease in the discovery of novel and 
effective antibiotics serves as motivation to develop alternative approaches in antimicrobial 
therapy (Walsh 2003; Fischbach and Walsh 2009).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Bacteriocins are separated from antibiotics by several factors, including mode of action and 
binding sites (Brötz et al. 1998; Shai 2002; Hsu et al. 2004). Bacteriocins are usually active 
against specific species, often those closely related to the producer strain, whereas antibiotics 
have a broad range of activity. Bacteriocins are, however, active at nanomolar concentrations, 
whereas antibiotics are required at much higher concentrations (Brötz et al. 1998). Bacteriocins 
from Gram-positive bacteria, especially lactic acid bacteria (LAB), have generated the most 
attention over the past years.  The GRAS (generally regarded as safe) status of these organisms, 
their application in the food industry and as probiotics, has led to a vast increase in research 
activities, also on the antimicrobial peptides they produce. Some bacteriocins have activity 
against MDRP, such as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant 
enterococci (VRE) (Kruszewska et al. 2004; Piper et al. 2010). In addition to MDRP, some 
bacteriocins have also indicated activity against other clinical strains (Knoetze et al. 2008; De 
Kwaadsteniet et al. 2009).  
Bacteriocins are grouped into three main classes (Klaenhammer 1993; Chen and Hoover 2003; 
Cotter et al. 2005). Class I bacteriocins are defined as lantibiotics and are divided into subgroups 
A and B based on structure and mode of action (Cotter et al. 2005). Class II bacteriocins are 
heat-stable, non-lanthionine-containing peptides and are separated into four subgroups (Bauer 
and Dicks 2005). Pediocin-like bacteriocins are grouped into class IIa, bacteriocins that require 
two peptide for activity are grouped in class IIb, cyclic peptides in class IIc and single non-
pediocin like peptides in class IId (Van Reenen et al. 2003; Cotter et al. 2005;  Albano et al. 
2007). Class III contains the bacteriolysins (Cotter et al. 2005).  
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The use of bacteriocins is therefore a possible alternative to antibiotics. There are, however, 
several issues that have to be addressed if bacteriocins are to be used in vivo for the treatment of 
infection. Bacteriocins are sensitive to degradation by proteases and other degrading enzymes 
(Gupta and Batish 1992; Joerger 2003). Therefore, it is important to protect them from possible 
degradation. Another problem is the mechanism by which the bacteriocins are delivered. One 
possible solution to this problem is the use of polymeric delivery systems (Bilati et al. 2005; 
Yoshida et al. 2006; Kanczler et al. 2007; Heunis et al. 2010; Heunis et al. 2011). Microparticles 
are able to prolong the activity of nisin in vitro and may be able to protect them from degradation 
(Salmaso et al. 2004). It has also been shown that microparticles are able to protect encapsulated 
plasmid DNA from degradation in vivo (Garcia del Barrio et al. 2003). The use of polymeric 
drug delivery systems such as micro or nanoparticles, and nanofibers, has been proven to be 
effective drug delivery systems in vitro and may be advantageous for the delivery of bacteriocins 
(Salmaso et al. 2004; Bilati et al. 2005; Garcia del Barrio et al. 2003; Freiberg and Zhu 2004; 
Siepmann et al. 2004; Zhang et al. 2008, Heunis et al. 2010; Ye et al. 2010; Heunis et al. 2011). 
There are several factors that may influence the production method used, and when working with 
proteins, non-degrading methods must be chosen.  
This review discusses the main classes of bacteriocins produced by LAB and their possible 
clinical applications. Polymeric micro- or nanoparticle production and their applications will also 
be investigated.  
Bacteriocins produced by lactic acid bacteria 
The increase in number of bacteriocins discovered over the last decade is testimony of the large 
variety amongst these peptides. Several classification schemes have been proposed for 
bacteriocins produced by Gram-positive. The most widely excepted classification scheme was 
proposed by Klaenhammer (1993; Table 1). Recently an update of Klaenhammer‟s classification 
system has been proposed by Cotter et al. (2005). They suggest that there are only two 
bacteriocin classes produced by Gram-positive bacteria. Rea et al. (2011) have also suggested a 
rational scheme, taking into account all current classification systems (Table 2). The updated 
classification scheme proposed by Rea et al. (2011) is discussed. 
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Class I bacteriocins 
According to previous classification systems, class I only contains heat stable post-
translationally modified bacteriocins of which only lantibiotics were included (Klaenhammer 
1993). In the updated schemes class I are subdivided into three subclasses which can be further 
subdivided into subsequent subclasses (Rea et al. 2011).  
Class Ia 
Class Ia consists of the lantibiotics and lantipeptides. These peptides contain the unusual amino 
acids lanthionine, and/or β-methyllantionine as well as dehydrobutyrine (Rea et al. 2011). In 
previous systems lantibiotics was classified according to structure as either type A or B (Jung 
1991). Type A lantibiotics are elongated, amphiphilic, cationic peptides, illustrating activity via 
pore formation and subsequent dissipation of the proton motive force (Jung 1991; McAuliffe et 
al. 2001). Type B lantibiotics consists of short, globular peptides, demonstrating activity through 
enzymatic inhibition of cell wall biosynthesis (Jung 1991; McAuliffe et al. 2001). Research into 
the mode of action of these peptides illustrated some drawbacks to the classification system. 
Nisin, for example, creates pores in the membrane which makes it a type A lantibiotic (Brötz et 
al. 1998; Hasper et al. 2004). However, it is also capable of inhibiting peptidoglycan synthesis 
by binding to lipid II, which classes it as a type B lantibiotic (Brötz et al. 1998; Breukink et al. 
2003). Lacticin 3147 is a two peptide lantibiotic which first targets lipid II (peptide Ltn-α) and 
this complex then initiates binding of Ltn-β which results in inhibition of cell wall synthesis as 
well as pore formation (Morgan et al. 2005). The mode of action of lacticin 3147 and nisin can 
therefore class them as both type A and type B. The update classification system divides class Ia 
peptides into four main subclasses according to their biosynthetic and export machinery (Table 2 
and 3). Subclass I and II can be further subdivided according to amino acid sequences (Rea et al. 
2011). 
Class Ib 
Class Ib or the labyrinthopeptins consists of a new class of post-translationally modified 
peptides. The newly identified labyrinthopeptins are distinguished by their labyrinth type 
structure containing a carbacyclic post-translationally modified amino acid namely; labionin 
(Meindl et al. 2010). Meindl et al. (2010) illustrated antiviral activity of labyrinthopeptin A2 
(produced by Actinomadura namibiensis) as well as its ability to treat neuropathic pain in mice. 
Class Ic 
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The small post-translationally modified cyclic peptide subtilosin A was not taken into 
consideration in previous classification schemes due to its unusual cysteine to α-carbon bridges 
(Kawulka et al. 2004). A new two-peptide bacteriocin thuricin CD has also been found to have 
cysteine to α-carbon linkages as seen in subtilosin A (Rea et al. 2010). Subtilosin A as well as 
identification of thuricin CD justifies inclusion of this emerging group in future classification 
systems. Rea et al. (2011) therefore proposed that these bacteriocins namely; sulphur to α-carbon 
linkage-containing antibiotics should be classed as sactibiotics (class Ic). They are further 
subdivided into two subclasses, single- and two-peptide bacteriocins. 
Class II bacteriocins 
Class II is a large heterogeneous group of bacteriocins, consisting of standard amino acid 
residues and heat stable bacteriocins. The traditional classification system has three classes; IIa 
containing the pediocin like bacteriocins, IIb made up the two-peptide bacteriocins and IIc 
contains the thiol activated bacteriocins (Klaenhammer 1993). Others have suggested that class 
IIc contain all the class II bacteriocins that do not fit into IIa or b (Nes et al. 1996, Eijsink et al. 
2002). The updated scheme redefines class IIc as the cyclic bacteriocins and adds class IId which 
contain the non-pediocin single linear peptides (Tables 2 and 4; Cotter et al. 2005; Rea et al. 
2011). 
Class IIa 
These bacteriocins have a narrow range of activity but are highly potent against sensitive strains. 
They share a conserved hydrophilic, cationic sequence at the N-terminal, referred to as the 
“pediocin box” containing two cysteines joined by a disulfide bond (-Y-G-N-G-V-X1-C-X2-K/N-
X3-X4-C-; X1-4 represents polar uncharged or charged residues; Papagianni and Anastasiadou 
2009). Other than this and the cleavage of the leader peptide, the peptides are unmodified. The 
hydrophobic/amphiphilic C-terminal is, however, not as conserved as the N-terminal (Fimland et 
al. 1996). Recent results suggest that the N- and C-terminal act independently and that the C-
terminal of the bacteriocin is important for target specificity (Johnsen et al. 2005). The N- and C-
terminal domains are separated by a flexible hinge and allows flexibility to enable insertion of 
the C-terminal into the hydrophobic region of the membrane (Uteng et al. 2003). Retention of 
the α-helix in the C-terminal seems to play a critical role in activity, most likely by formation of 
ion pores resulting in dissipation of the PMF (Chikindas et al. 1993; Johnsen et al. 2005). 
Class IIb 
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Class IIb bacteriocins are mainly produced by LAB and range from 30-50 amino acid residues 
(Nissen-Meyer et al. 2009). They are all two-peptide bacteriocins with the genes encoding the 
two peptides found next to each other and the immunity gene adjacent on the same operon 
(Franz et al. 2002). The peptides are synthesized with an N- terminal leader peptide consisting of 
15-30 residues (double-glycine type) and cleaved at the C-terminal side of two glycine residues 
upon export of the peptides outside the cell (Oppegard et al. 2007). The peptides are inactive on 
their own and need to physically interact to form an active two-peptide bacteriocin, there are 
however examples where one or both peptides show low individual activity (Nissen-Meyer et al. 
1992; Anderssen et al. 1998; Oppegard et al. 2007). Mode of action of these bacteriocins has 
been shown to be permeabilisation of the cell membrane leading to dissipation of the PMF (Moll 
et al. 1996; Moll et al. 1999; Nissen-Meyer et al. 2009). It has been suggested that the two 
peptides interact through conserved GxxxG or “GxxxG like” motives present on both peptides 
and interrupting this interaction results in reduced activity (Rogne et al. 2009). 
Class IIc 
Class IIc bacteriocins in older schemes contained the thiol-activated bacteriocins requiring 
reduced cysteine residues for activity (Klaenhammer 1993). In other proposals it was suggested 
that all bacteriocins that do not fit into class IIa or IIb must be classed as IIc (Eijsink et al. 2002). 
In the updated system class IIc contains the cyclic antimicrobial peptides (ribosomally 
synthesized). Post-translational modification of these peptides results in their N- and C-terminal 
to be linked resulting in a circular backbone (Martinez-Bueno et al. 1994; van Belkum et al. 
2011). Class IIc can further be divided into IIc (1) or IIc (2) based on their amino acid sequences 
(Cotter et al. 2005).  
Class IId 
Class IId enlists all unmodified, linear, non-pediocin-like one peptide bacteriocins which do not 
conform to the criteria set out for other class II bacteriocins (Cotter et al. 2005). Consequently 
this class contains a large number of heterogeneous antimicrobial peptides from a variety of 
strains and a range of ecological niches.  
Bacteriolysins 
The bacteriolysins are large and heat sensitive peptides with a domain-type structure with 
different components of the molecule functioning in translocation, receptor binding and 
antimicrobial activity (Simmonds et al. 1997). Bacteriolysins cleave the peptidoglycan protein 
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moiety of sensitive organisms resulting cell wall lysis (Beukes et al. 2000; Simmonds et al. 
1996). There are five bacteriolysins produced by LAB, helveticin J (Lactobacillus helveticus; 
Joerger and Klaenhammer 1986), zoocin A (Streptococcus zooepidemicus; Simmonds et al. 
1996), enterolysin A (Enterococcus faecalis; Hickey et al. 2003), millericin B (Sterptococcus 
milleri; Beukes et al. 2000) and linocin M18 (Brevibacterium linens; Valdes-Stauber and Scherer 
1994). They share an N-terminal domain responsible for enzymatic activity that has homology to 
endopetidases, whereas the C-terminal is thought to contain the cell wall binding domain, as seen 
with the broad range of activity of enterolysin A compared to zoocin A (Hickey et al. 2003; 
Beukes et al. 2000; Simmonds et al. 1997).  
Classification schemes of bacteriocins will continue to evolve, with increase knowledge of the 
structure of bacteriocins as well as advancements in molecular biology.  
Micro or nanoparticles as polymeric protein delivery systems 
Biodegradable and biocompatible polymeric particles have gained great interest as delivery 
systems for bioactive molecules, especially micro- and nanoparticles. Conventional delivery 
methods for bioactive molecules usually require daily doses to reach a level that would be 
considered therapeutic. With polymeric delivery systems, the release of the molecule can be 
delayed, requiring less frequent treatments, which may reduce patient non-compliance (Freiberg 
and Zhu 2004). A wide range of polymers in use are associated with bioactive agents including; 
poly (lactic acid) (PLA), poly (lactic-co-glycolic acid) (PLGA) and poly (ethylene oxide) (PEO) 
(Almeida et al. 1993; Salmaso et al. 2004; Schnieders et al. 2006; Yoshida et al. 2006). Particles 
prepared from these polymers proved to be effective in in vivo trials (Pandey et al. 2003; Ruhe et 
al. 2005; Schluep et al. 2009). Pandey et al. (2003) have shown that anti-tubercular drugs 
encapsulated in PLGA could be used to treat Mycobacterium tuberculosis. Loaded particles were 
administered every 10 days and indicated therapeutic activity throughout. Formulations like 
these may reduce patient non-compliance, lower production cost and increase drug delivery 
effectiveness. In another study, nisin was encapsulated in PLA nanoparticles (Salmaso et al. 
2004). Loaded nanoparticles have shown prolonged antibacterial activity, indicating controlled 
release as well as retention of biological activity of the peptide (Salmaso et al. 2004). Bioactive 
agents such as recombinant human bone morphogenetic protein-2 (Ruhe et al. 2003), insulin 
(Builders et al. 2008), and platelet derived growth factor and vascular endothelial growth factor 
(Kang et al. 2008; De la Riva et al. 2010; Richardson et al. 2001) have all been encapsulated into 
micro or nanoparticles. The release kinetics of various antibiotics have also been investigated in 
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polymeric particle systems (Pandey et al. 2003; Yoshida et al. 2006; Arnold et al. 2007; 
Tsifansky et al. 2008) 
Micro or nanoparticle fabrication 
There are several methods to produce polymeric particles; the type of method will depend on the 
bioactive agent as well as the desired particle characteristics. Another important factor to 
consider is the polymer and solvent to be used for fabrication. Each bioactive agent will react 
differently to the polymer used as well as the solvent (Blanco and Alonso 1998; Ye et al. 2010). 
The polymer: solvent: bioactive agent solution will also affect particle characteristics and 
fabrication method (Griebenow and Klibanov 1996; Birnbaum et al. 2000; Jeon et al. 2000; 
Castellanos et al. 2003; Siepmann et al. 2004; Xu and Hanna 2006; Kang et al. 2008).  
There are several ways to produce micro- or nanoparticles; the main methods are expanded 
below. 
Electrospray method 
Electrospraying and electrospinning follow the same basic principles in terms of 
electrohydrodynamic atomization (Morota et al. 2004; Xie and Wang 2007; Heunis et al. 2010). 
An electric field is passed through a polymer solution resulting in the formation of a meniscus 
(Taylor cone) at the tip of the needle. The jet emerging from the apex will then break and 
disperse as separate particles repelled by electrostatic forces (Xu and Hanna 2006; Xie and Wang 
2007). The particles are then collected on a grounded collector. The characteristics of particles 
can be altered by changing parameters such as solvent and polymer (concentration, MW and 
composition) and potential difference through the polymer solution (Morota et al. 2004; Xu and 
Hanna 2006; Wu and Clark 2007). Examples of protein encapsulation include Bovine serum 
albumin into PLA and PLGA (Xu and Hanna 2006; Xie and Wang 2007). It has also been 
illustrated that electrospinning bacteriocin 423 results in active peptide with controlled release 
(Heunis et al. 2010; Heunis et al. 2011). Electrospraying for the encapsulation of proteins has 
not yet been used to its full potential and may prove useful in fabrication of delivery systems. 
Water/oil/water double emulsion method 
In the W/O/W method an aqueous protein/drug solution is dispersed into a polymer solution (e.g. 
PLGA dissolved in dichloromethane) resulting in the first W/O emulsion. The W/O emulsion is 
added to a large volume of water containing an emulsifier such as poly (vinyl alcohol), this 
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forms a W/O/W emulsion (Ruhe et al. 2003). Removing the organic phase by either solvent 
extraction or solvent evaporation will result in hardened particles (Cleek et al. 1997; Ruhe et al. 
2003; Basarkar et al. 2007). Particle properties can be changed by altering the following 
parameters; protein concentration and type, polymer (concentration, MW and composition), 
solvent (type and concentration), ratio between protein and polymer and emulsification 
procedure (intensity and duration; Yang et al. 2001; Ito et al. 2007; Ye et al. 2010). Several 
bioactive molecules have been encapsulated using this method including; insulin, BSA as well as 
plasmid DNA (Cleek et al. 1997; Rafati et al. 1997; Ito et al. 2007; Teply et al. 2008,). This 
method uses inexpensive equipment and is relatively simple, however due to the technique 
protein encapsulation may not always be high. 
Solid/oil/water method 
This technique is used to try and prevent protein denaturisation at the solvent/water interface 
(Castellanos et al. 2003). When proteins are in a solid state it is assumed that their 
conformational mobility is reduced resulting in retention of bioactivity (Griebenow and Klibanov 
1996; Castellanos et al. 2003). Solid protein or drug (crystals or powder) are added to a polymer 
solution to form the first emulsion (Castellanos et al. 2003; Siepmann et al. 2004). The primary 
emulsion is then placed in a large volume of water containing an emulsifier such as poly (vinyl 
alcohol). The organic phase is then removed as with W/O/W method (Siepmann et al. 2004). 
Micronization is an important parameter with this technique; it has been shown that reduction in 
the protein particle size influences encapsulation efficiency as well as release kinetics (Birnbaum 
et al. 2000; Takada et al. 2003). 
Spray drying and spray freeze drying methods 
In spray drying a protein solution or emulsion (S/O or W/O) is sprayed at an elevated 
temperature to facilitate solvent evaporation and subsequent particle atomization (Gander et al. 
1995; Carrasquillo et al. 2001; Ye et al. 2010). This is a one-step method that has easy control 
over parameters that control particle characteristics (Ye et al. 2010). Proteins may be denatured 
at high temperatures required for solvent evaporation (Mumenthaler et al. 1994; Quaglia et al. 
2003; Ye et al. 2010). Using this method particles containing insulin, BSA, tetanus toxoid and 
recombinant human erythropoietin have been encapsulated (Quaglia et al. 2003; Gander et al. 
1995; Bittner et al. 1998; Johansen et al. 1998; Ye et al. 2010). 
Spray freeze drying avoids high temperatures, but is much more complicated than the one step 
spray drying (Carrasquillo et al. 2001). Protein is first sprayed into liquid N2 and lyophilized; 
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protein particles are then added to polymer solution to make an S/O emulsion. The S/O emulsion 
is then sprayed using an ultrasonic nozzle into a bath containing frozen ethanol overlaid with 
liquid N2. The bath is then placed at -80°C where ethanol melts and solvent extraction begins. 
The particles are solidified and dried by passing through nitrogen at 2 to 8°C (Costantino et al. 
2000). This method may exert stresses on proteins that may result in instability (Costantino et al. 
2000; Ye et al. 2010)   
Supercritical CO2 particles  
This technique exploits the properties of a solvent at near critical or supercritical state. A 
substance is at a supercritical state when its pressure and temperature is greater than its critical 
pressure (Pc) and temperature (Tc), respectively (Benedetti et al. 1997). In the supercritical state 
the supercritical fluid (SCF) exhibits both gas- and fluid-like properties. For pharmaceutical 
purposes carbon dioxide is an ideal SCF, as it has a low Tc (31.5C) and Pc (73.8 bar), which is 
industrially feasible and non-toxic (Benedetti et al. 1997). Carbon is a non-polar solvent, 
therefore it is not able to dissolve polar substance; in which case a different supercritical liquid 
can be used or a co-solvent can be added to increase the solubility properties of CO2 (Benedetti 
et al. 1997). Two basic techniques are used in the production of particles using scCO2; e.g. rapid 
expansion of supercritical solutions (RESS) and supercritical antisolvent process (SAS).  
When using RESS, a non-volatile solute is dissolved in the SCF (supercritical fluid). The 
solution is then extruded at high velocity through a capillary/nozzle, as the pressure rapidly 
decreases solvent-free particles precipitate (solute nucleation; Benedetti et al. 1997). The 
disadvantage of RESS is the low solubility of various polar pharmaceutical compounds 
(including polymers) and the large amount of CO2 needed (Sekhon 2010). A co-solvent can be 
added to the CO2, but this however takes away RESS‟s solvent free advantage (Benedetti et al. 
1997; Mishima et al. 2000).    
SAS requires an organic solvent, in addition to the SCF and the solid solute (Benedetti et al. 
1997). The solute is dissolved in the organic solvent which is then added to the SCF which is 
miscible with the solvent but not the solute, resulting in the precipitation of the solute (Benedetti 
et al. 1997). Two methods are used for the precipitation of the solute; gas anti-solvent (GAS) 
precipitation and precipitation with compressed anti-solvents (PCA). In the GAS method high 
pressure CO2 is added to the solvent: solute solution resulting in a volumetric expansion of the 
liquid phase and the precipitation of the solute (Elvassore et al. 2001; Fusaro et al. 2005). In the 
PCA method the solvent: solute solution is sprayed into a SCF, resulting the rapid two-way mass 
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transfer (SCF diffusing into solute and solute diffusing into SCF) results in supersaturation of the 
solute and its precipitation (Jarmer et al. 2003; Fusaro et al. 2005).  
A wide variety of pharmaceutical compounds have been used in both GAS and PCA, including 
nisin (using PCA; Elvassore et al. 2001; Salmaso et al. 2004; Lee et al. 2008).   
Future prospects for bacteriocins and micro or nanoparticle delivery systems 
The discovery of antimicrobials plays a crucial role with the increase in antibiotic resistant 
microorganisms. The role new antimicrobial peptides, such as bacteriocins, may play in 
treatment of resistant pathogens may be invaluable. The discovery of new antibiotics over the 
past few decades does not look promising and mostly relies on the development of synthetic 
antibiotics (Fischbach and Walsh 2009). The identification of novel bacteriocins that may be 
active against resistant pathogens is however on the increase (Chen and Hoover 2003). Research 
into their discovery, testing (safety) and characterization is therefore essential. Sensitivity of 
bacteriocins to degradation in vivo is a drawback for their use in the treatment/prevention of 
infection (De Kwaadsteniet et al. 2009; Brand et al. 2010; De Kwaadsteniet et al. 2010). Future 
research has to focus on selecting for more robust broad spectrum bacteriocins that are capable 
of remaining active in vivo.  Identifying the major factors involved in their in vivo degradation 
may also provide insight into how to select bacteriocins for in vivo applications. 
Polymeric delivery systems may provide the solution to degradation of bacteriocins in vivo. The 
development of more effective and efficient ways to treat disease is essential if the medical 
industry to evolve. The use of micro and nanoparticles to provide controlled release and 
protection of bioactive agents may present possible improvements in treatment (Pandey et al. 
2003; Salmaso et al. 2004; Ye et al. 2010). With the increase of drug effectiveness using 
polymeric particles parameters such as cost, patient compliance and effective treatment all 
benefit. 
Research into the combination of polymeric drug delivery systems, such as particles and 
bacteriocins is ongoing. An important factor is to make sure that these combinations actually 
work in an in vivo situation. In vivo experiments are therefore essential to lay the ground work 
for the eventual use of bacteriocins and polymer systems in the treatment of infections. Although 
bacteriocins are able to kill sensitive organisms it is important to realize that resistance to these 
peptides are possible. It has been shown that organisms obtaining resistance to bacteriocins 
indicate increase resistance to antibiotics. The combination of antibiotics and bacteriocins must 
also be investigated; these combinations may lead to more effective antimicrobials.  
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Table 1: Original classification scheme of Klaenhammer 1993 (from Rea et al. 2011) 
Class Description Distinctive features 
Class I Post-transcriptionally modified 
bacteriocins 
Contain unusual amino acids 
lanthionine, and/or β-
methyllantionine and 
dehydrobutyrine  
Class II Unmodified peptides Small (<10 kDa) heat stable 
membrane active peptides 
Class III Unmodified proteins Large (>30 kDa) heat liable 
proteins 
Class IV Complex proteins Contains lipid or carbohydrate 
moieties  
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Table 2: Updated classification scheme for Gram-positive bacteriocins and bacteriocin-like peptides and 
proteins (adapted from Rea et al. 2010) 
Class Description Subdivision 
Class I Modified peptides  
 a. Lantibiotics and 
lantipeptides 
Subclass I and II based on modification of pre-peptides 
with LanB, LanC (I) and LanM (II). Can be further divided 
into 12 subclasses based on aa sequences. 
 
Subclass III and IV based on modifications with RamC-like 
(III) LanL (IV) proteins. 
 b. Labyrinthopeptins  
 c. Sactibiotics Single- and two-peptide bacteriocins 
Class II Non-modified peptides  
 a. Pediocin-like 
bacteriocins 
Four subclasses I-IV 
 b. Two-peptide 
bacteriocins 
Two subclasses; A and B 
 c. Circular bacteriocins Two subclasses; 1 and 2 
  d. Linear-non pediocin-
like single 
bacteriocins 
 
Bacteriolysins Non-bacteriocin lytic 
proteins 
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Table 3:  Class I subclasses and lantibiotic groups in each class  (adapted from Piper et al. 2009 and 
Rea et al. 2011) 
Class and Subclass Lantibiotic group or peptide 
Class Ia  
Subclass I Nisin, planosporicin, epidermin, Pep5 and 
streptin. 
Subclass II Lacticin, mersacidin, LtnA2, cytolysin, lactosin S, 
cinnamycin and sublancin. 
Subclass III RamS, SapT and AmfS. 
Subclass IV Venezuelin. 
Class Ib (Labyrinthopeptins) Labyrinthopeptins A1 and A2. 
Class Ic (Sactibiotics) Subtilosin A (single-peptide) and Thuricin CD 
(two-peptide). 
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Table 4: Class II subclasses and main bacteriocins in each class  (adapted from Martin-Visscher et al. 
2009 and Nissen-Meyer et al. 2009) 
Class and Subclass Main bacteriocins in subclass 
Class IIa  
Subclass I Coagulin, divergicin (M35 and V41), enterocin 
A, leococin C, listeriocin 743 A, munticin (- and 
KS), pediocin PA-1, pisciocin CS 526, piscicolin 
126 and sakacin (P and 5X). 
Subclass II Lactococcin MMFII, leucoccin A, mesentericin 
Y105, plantaricin (423 and C19), sakacin G. 
Subclass III Curvicin A, Carnobacteriocin BM1 and enterocin 
P 
Subclass IV Bacteriocin 31, bacteriocin RC714, bacteriocin 
T8, penocin A, enterocin SE-K4 and 
carnobacteriocin B2. 
Class IIb (Two-peptide bacteriocins)  
Subclass A ABP-118, brochocin C, lacticin F, lactocin 705, 
mutacin IV, plantaricin (E/F, J/K, NC8 and S), 
Salvaricin P and thermophilin 13. 
Subclass B Lactococcin (G and Q) and entrocin 1071. 
Class IIc (Circular bacteriocins)  
Subclass 1 Carnocyclin A, circularin A, enterocin AS48, 
uberolysin and lactocyclicin Q.    
Subclass 2 Butyrivibriocin AR10, gassericin A, reutericin 6 
and acidocin B
1
. 
Class IId ( Linear-non pediocin-like single 
bacteriocins) 
Lactococcin (A, B and 972), Enterocin (B, EJ97, 
L50A, L50B, Q and RJ-11), Carnobacteriocin A, 
Bac32, Aureocin (A70 and A53), Lacticin (Q and 
Z), BHT-B, Acidocin (A, 1B and CH5), 
Bacteriocin OR-7, Divergicin 750, Weissellicin 
110, Cripacin A, Lacticin RM, Micrococcin GO5, 
Lsb (A and B) Mesenterocin 52B, Mesentericin 
B105, Dextranicin 24, Leucocin B-TA33a, 
Bovicin 255. 
1
 Circular structure not yet determined but has 98% sequence identity to gassericin A and reutericin 6. 
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Abstract   
Maxillofacial and craniofacial surgery is on the increase, which exposes more patients at risk of 
acquiring microbial infections. The use of antibiotic loaded calcium phosphate bone cements 
have been shown to reduce the incidence of infection. A marked increase in antibiotic resistant 
pathogens, including multidrug-resistant pathogens, has been reported. This has led to the 
investigation of various compounds as alternatives to conventional treatments. In this paper we 
report on the incorporation and release of a broad-spectrum class II antimicrobial peptide, 
bacteriocin ST4SA produced by Enterococcus mundtii, into a calcium orthophosphate-based 
bone cement (CPC). Our results suggest class II bacteriocins may be incorporated into self-
setting bone cements to produce implants with antimicrobial activity over extended periods of 
time. 
Keywords   
Bacteriocin, Brushite Bone Cement, Antimicrobial Activity 
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Introduction 
With the increase in life expectancy, orthopedic implant surgery is on the rise, which in turn puts 
more patients at risk of acquiring microbial infections [17, 26]. In maxillofacial and craniofacial 
surgery, antibiotics are usually administered prophylactically to prevent post-operative 
infections. However, the increase in the number of antibiotic resistant bacteria, especially 
methicillin-resistant Staphylococcus aureus (MRSA), has narrowed the choice of antibiotics 
down to only a few [13, 14, 26, 34]. Furthermore, antibiotics administered intravenously or 
orally are not always effective [13, 14]. The main reason for this is the restriction in blood flow 
in areas surrounding the implant, and hence less contact between the antibiotic and site of 
infection [14, 37]. In severe cases of infection, surgical intervention is often the only alternative 
to a cure [37, 38]. 
A number of papers have been published on the incorporation of antibiotics and therapeutic 
agents in bone cement [2, 6, 15, 18, 20, 32, 33, 36]. Thornes and co-workers [34] observed a 
decrease in Streptococcus epidermis infection with gentamicin incorporated into bone cement 
(41% infection rate compared to 73% in the absence of gentamicin). However, the number of S. 
epidermis cells that developed resistance to gentamicin increased from 19% to 78% [34]. In 
other studies antibiotic-loaded bone cements used as a prophylactic significantly reduced the 
incidence of prosthetic joint associated infection [13, 19]. 
Bacteriocins with a broad or narrow spectrum of activity, and mechanisms of action different 
from conventional antibiotics, may serve as an alternative in the treatment of antibiotic resistant 
pathogens. Some of these peptides have shown activity against MRSA, vancomycin resistant 
enterococci as well as other clinical isolates [7, 11, 22, 23, 28]. Most of the bacteriocins are 
small, ribosomally synthesized, cationic and hydrophobic/amphiphilic peptides with 20 to 60 
amino acid residues. They are grouped into two main classes [9, 10, 21]. Class I bacteriocins are 
defined as lantibiotics and are divided into subgroups A and B based on structure and mode of 
action [10]. Class II bacteriocins are heat-stable, non-lanthionine-containing peptides and are 
separated into four subgroups [4]. Pediocin-like bacteriocins [1, 35] are grouped into class IIa, 
bacteriocins that require two peptide for activity are grouped in class IIb, cyclic peptides in class 
IIc and single non-pediocin like peptides in class IId [10]. Class III contains the bacteriolysins 
[10]. 
Bacteriocin ST4SA, produced by Enterococcus mundtii ST4SA, belongs to the class IIa 
bacteriocins, and is active against various Gram-positive bacteria, including S. pneumonia and S. 
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aureus, as well as the Gram-negative bacterium Pseudomonas aeruginosa [22]. This paper 
describes the incorporation of bacteriocin ST4SA in calcium orthophosphate-based cement 
(CPC) and reports on the release rate and antimicrobial activity of the peptide in vitro. We have 
chosen CPC due to its excellent osteoconductive properties and stability during in situ molding 
[29]. Furthermore, CPCs are usually resorbed by osteoclasts and do not need to be removed, thus 
reducing the risk of infection caused by secondary operations [8, 27]. 
Materials and Methods 
The β-tri calcium phosphate (βTCP, 95%) and monocalcium phosphate monohydrate (MCPM, 
85%) was acquired from Sigma-Aldrich (Sigma-Aldrich, Germany). Tri-sodium citrate dihydrate 
was obtained from Saarchem (Saarchem, Gauteng, South Africa), and ammonium sulfate 
(99.5%) and Listeria Enrichment Broth (LEB) from Merck (Merck, Darmstadt, Germany). 
Dialysis membranes (1 kD, Spectra/Por® 6) were from Spectrumlabs (Spectrum Inc., CA, USA). 
The BCA protein assay kit was from Thermo Scientific (Pierce Biotechnology, Rockford, IL, 
USA). All other growth media used were from Biolab (Biolab Diagnostics, Midrand, South 
Africa). 
Preparation of Bacteriocin ST4SA 
E. mundtii ST4SA was cultured in 1 L MRS broth
 
for 24 h at 30°C. Cells were harvested at 8000 
g for 10 min at
 
4°C.  The pH of the resulting supernatant was adjusted to 6.5-7.0 and then 
incubated at 80°C for 10 min to inactivate proteolytic enzymes. Proteins were precipitated from 
the cell-free
 
supernatant with 80% saturated ammonium sulfate [25]. The precipitate
 
was 
collected by centrifugation (10000g for 1 h at 4°C) and the pellet re-suspended in 10 mL sterile 
distilled water. The concentrated bacteriocin was dialyzed against 4 L sterile distilled water 
using a 1 kDa cut-off dialysis membrane (Spectrumlabs). The dialyzed product was concentrated 
by freeze-drying and stored at -20°C. Antimicrobial activity
 
was determined by using the agar-
spot method [22]. Activity
 
was expressed in arbitrary units per mL (AU/mL). One AU is defined
 
as the reciprocal of the highest serial two-fold dilution showing
 
a clear zone of growth inhibition. 
Listeria monocytogenes EGD-e, grown in LEB supplemented with 7.5 µg/mL chloramphenicol, 
and incubated at 37°C on a shaker, was used as model sensitive strain. 
Preparation of Bone Cement 
Cement samples were prepared according to the method described by Barralet and co-workers 
[3]. β-TCP and MCPM were ground to a fine powder with a pestle and mortar and mixed in 
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equimolar amounts. The powder (250 mg) was mixed with 75.76 µL 500 mM tri-sodium citrate 
(P/L ratio of 3.3 g/mL), which served as retardant. Samples containing bacteriocin ST4SA were 
prepared by first adding the peptide to the dry cement powder (5%, w/w) before mixing with 500 
mM tri-sodium citrate. Mixing was performed on a glass slab for 30 seconds to form a 
homogeneous paste. The paste was moulded into insulin syringes, from which the tips have been 
cut off, and dried at 37°C for 2 h. The set cement cylinders were approx. 8 mm long and 4 mm in 
diameter. 
Characterization of Bone Cement 
The crystal structure of the bone cement was studied by using a Zeiss EVO MA15VP scanning 
electron microscope (SEM). The cement cylinders were fractured, placed on an adhesive stub 
and coated with gold before SEM analysis. Powder X-ray diffraction (XRD) patterns of the set 
cements were recorded on a PANalytical X‟Pert PRO MPD (Multi-Purpose Diffractomator). 
Data were collected from 2θ= 10° - 60° with a step size of 0.02° and a normalized count time of 
1 s/step using Cu Kaα radiation. Phase composition was checked by means of ICDD 
(international centre for diffraction data) reference patterns for β-TCP (00-009-0348), MCPM 
(01-070-0359), brushite (00-009-0077 & 01-072-0713) and hydroxyapatite (00-001-1008). 
Release of Bacteriocin ST4SA from Bone Cement 
Bone cement cylinders, made from 250 mg β-TCP/MCPM powder mixed with 12.5 mg 
bacteriocin ST4SA preparation, were incubated in 5 mL PBS buffer (pH 7.4) at 37°C and slowly 
stirred. At selected time intervals the entire volume of buffer was collected and centrifuged at 
8000 g for 1 min to remove non-dissolved particles. Protein concentration (mg/mL) in the 
particle-free buffer was determined by using the colorimetric BCA protein assay method at 562 
nm, to determine release of bacteriocin ST4SA. Readings were recorded from standard curves 
prepared with bovine serum albumin. Buffer extracted was replaced with fresh buffer and the 
bone cement cylinders incubated until the next reading. Readings were recorded over 120 h. 
Release of protein from the bone cement was expressed as percentage of the original protein 
content present in the sample. 
In a separate experiment, the bone cement cylinders were removed from the PBS buffer (pH 7.4) 
and inserted into 10 mL soft agar (1.0%, w/v), seeded with 1 mL L. monocytogenes EGD-e (1 x 
10
7
 cfu/mL). The plates were incubated at 37°C for 24 h and bacteriocin ST4SA activity 
recorded by formation of a clear zone of growth inhibition around the cement cylinders. 
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Antimicrobial Activity of Peptide ST4SA Released from Bone Cement 
To determine the rate at which bacteriocin ST4SA is released from the bone cement, a delayed-
agar diffusion method was used [5]. Bone cement (250 mg) containing 12.5 mg peptide ST4SA, 
equivalent to 102400 AU/mL, were incubated in 20 mL 1% LEB soft agar seeded with 1 mL L. 
monocytogenes EGD-e (1 x 10
7
 cfu/mL). After 24 h of incubation at 37°C, the diameter (cm) of 
growth inhibition zones was recorded. The cement cylinders were then aseptically removed and 
placed into fresh soft agar seeded with L. monocytogenes EGD-e. The experiment was repeated 
until no zones of growth inhibition zones could be detected. 
Statistical Analysis 
Data were collected in Microsoft Excel 2007 and data points, indicated with standard deviations, 
represent an average of three repeats. 
Results 
Cement Characteristics 
Addition of bacteriocin ST4SA to the β-TCP/MCPM powder produced a slightly more viscous 
cement paste compared to samples without the peptide. SEM of cement cylinders with and 
without bacteriocin ST4SA revealed similar textures, i.e. a dense surface with characteristic 
plates and blocks (Fig. 1A and B). XRD patterns corresponded well with that recorded for ICDD 
patterns of brushite (00-009-0077 & 01-072-0713), although some peaks for β-TCP (00-009-
0348) and MCPM (01-070-0359) could be seen in samples with and without bacteriocin ST4SA 
(Fig. 2). No peaks characteristic of hydroxyapatite were observed in any of the samples. 
Release of bacteriocin ST4SA from the bone cement 
Most of bacteriocin ST4SA (approx. 80%) was released from the bone cement during the first 12 
h (Fig. 3). This was followed by a 4% increase in release over the next 108 h. After 120 h of 
submersion in PBS buffer, bacteriocin ST4SA-loaded bone cement was still active, i.e. repressed 
the growth of L. monocytogenes (not shown). 
Bacteriocin ST4SA incorporated into the bone cement inhibited the growth of L. monocytogenes 
EGD-e for up to 13 consecutive days, as shown by clear zones of growth inhibition (Fig. 4A).  
Zone sizes ranged from 3.5 cm in diameter, reported at day 2, to approx. 1.7 cm in diameter on 
day 13 (Fig. 4B). 
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Discussion 
Incorporation of bacteriocin ST4SA into β-TCP/MCPM did not lead to drastic structural changes 
(Fig. 1), suggesting that crystal formation and setting of the cement was not altered. XRD results 
indicated that the main phase of the set cement is brushite and addition of bacteriocin ST4SA did 
not cause any significant changes (Fig. 2). Peaks for β-TCP and MCPM could be seen in control 
samples and bacteriocin ST4SA-loaded samples, possibly due to the presence of non-reacting 
starting material [6]. Similar results have been reported with the incorporation of other 
therapeutic agents in bone cement [24, 33]. 
Release of the active agent from bone cement depends on several factors, such as cement-drug 
interaction, porosity of the cement and solubility of the drug [16, 20, 33]. Release of most 
therapeutic agents from bone cement is characterized by a sudden burst, followed by slow 
release over several hours [6, 15, 20, 33, 36]. Rapid release of bacteriocin ST4SA (Fig. 3) 
suggests a high initial diffusion from the bone cement, which is supported by the small size (3.5 
kDa) of the peptide. Bacteriocin ST4SA, on the other hand, was not completely released from 
the bone cement, as evident by the prolonged antimicrobial activity recorded (Fig. 4B) as well as 
the release study (Fig. 3). The release profile of bacteriocin ST4SA out of the cement was 
slightly higher than that reported for other therapeutic agents in unmodified cement [6, 15, 20, 
33, 36]. Solubility also plays a major role in the release rate. Hofmann and co-workers [20] 
reported a higher burst release rate for vancomycin (80% in 24 h) as opposed to the less soluble 
ciprofloxacin (60% in 24 h). Concluded from results obtained in our study, bacteriocin ST4SA 
was released from bone cement for at least 120 h, suggesting that a certain percentage of the 
peptide takes longer to dissolve. It may also be that the cationic peptide adheres to the bone 
cement by electrostatic forces. However, XRD and SEM results did not indicate chemical or 
structural changes (Figs 2 and 3). Another possibility may be that the peptide is only released 
upon cement dissolution/resorption [20, 33]. L. monocytogenes EGD-e was used as a model 
pathogen in this study. In future in vitro and in vivo experiments Streptococcus epidermidis and 
S. aureus will be included. 
Release of bacteriocin ST4SA from the bone cement may be enhanced by incorporating the 
peptide into micro- or nanoparticles. The concept has been shown in several other studies [12, 
29-32]. The porosity of bone cement is easily changed by increasing the powder:liquid ratio, 
which in turn will enhance the release of a therapeutic agent [20]. 
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Conclusions 
Bacteriocin ST4SA proved stable and active for at least 13 days in β-TCP/MCPM cement. The 
possibility of incorporating bacteriocins into bone cement and developing implants with inherent 
antimicrobial activity seems possible. The challenge would be to select antimicrobial peptides 
with broad-spectrum activity that would not elicit a host immune response and with a mode of 
action that would prevent the emergence of microbial resistance. The possibility of combining 
antibiotics with a suitable bacteriocin may also reduce the chances of microbial resistance. 
Encapsulation of antimicrobial peptides with micro- and nanoparticles in vitro as well as in vivo 
trials with mice are currently being investigated. 
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Fig. 1  SEM images (5.00K) of fractured cement samples without (A) and with (B) bacteriocin 
ST4SA (5%, w/w) 
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Fig. 2  XRD patterns of unloaded (control) cement samples and bacteriocin ST4SA-loaded 
samples (protein). Red lines indicate main brushite peaks (ICDD 00-009-0077) 
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Fig. 3  Cumulative release of bacteriocin ST4SA (5%, w/w) from brushite cement, expressed as 
a percentage of the original protein content 
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Fig. 4A  Antimicrobial activity of bacteriocin ST4SA incorporated into brushite cement. L. 
monocytogenes EGD-e served as sensitive strain. Images of antimicrobial activity are as 
recorded on days 1, 8 and 13 
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Fig. 4B  Release of peptide ST4SA (5%, w/w) from brushite cement over 13 days. L. 
monocytogenes EGD-e served as sensitive strain 
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Abstract 
Aims: To determine if peptide ST4SA-poly (D, L lactice-co-glycolide) (PLGA) microparticles 
could be incorporated into self-setting brushite bone cement and if peptide ST4SA will be 
released in its active form. 
 Methods and Results: Peptide ST4SA was suspended in an N, N-Dimethylformamide PLGA 
solution and electrosprayed to produce ST4SA-associated PLGA microparticles (SPM). Brushite 
cement was prepared by mixing equimolar concentrations of β-tricalcium phosphate and 
monocalcium phosphate monohydrate. SPM was added to brushite cement, to a concentration of 
10% (w/w), and moulded into cylinders. Release of peptide ST4SA from the cement and 
microparticels was determined by using BCA protein assay. Based on SEM analysis SPM had an 
average size of 1048∙4 nm and did not significantly affect crystal entanglement when added to 
the cement. According to XRD analysis the addition of SPM to the cement did not interfere with 
the setting reaction.  After the first 12 h, 36∙5% and 23∙2% of the total bacteriocin was released 
from particles and brushite-SPM composites, respectively. This was, followed by a 1∙6% and a 
7∙9% release over the next 228 h (for particles and brushite-SPM composites, respectively). 
Activity of the particles and cement was tested against a sensitive strain embedded in soft agar. 
Particle and brushite-SPM composites released active bacteriocin and inhibited the growth of L. 
monocytogenes EGD-e. 
Conclusions: Electrospraying was successfully used to generate ST4SA-associated PLGA 
submicron particles able to release active bacteriocin, when incorporated into brushite bone 
cement. 
Significance and Impact of the Study: ST4SA-associated PLGA particles prolong the release 
of ST4SA when incorporated into brushite bone cement and may provide protection to the 
peptide. 
Keywords 
Peptide ST4SA, brushite bone cement, in vitro activity, poly (D, L lactice-co-glycolide), 
microparticles 
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Introduction 
Infections associated with orthopedic surgery are difficult to treat and result in increase cost and 
morbidity (Cosgrove and Carmeli 2003, Frommelt and Kühn 2005, Jiranek et al. 2006, Zimmerli 
2006). Antibiotic-loaded bone cements have been used with some success as a prophylactic in 
various orthopedic procedures (van de Belt et al. 2001). The main cement type used in 
orthopedics is polymethylmethacrylate (PMMA) based, which is a non-resorbable polymer (Van 
de Belt et al. 2001). Calcium phosphate cements (CPC) have several advantages over the 
traditional PMMA cements, of which bioresorbability and biocompatibility are the most 
important (Theiss et al. 2005). CPC unfortunately suffer from low mechanical strength as appose 
to PMMA cements and are only used in low load bearing areas (Schmitz et al. 1999). CPC have, 
however, been used clinically with some success and have been included in several in vitro and 
in vivo studies (Miyamoto et al. 1995, Ohura et al. 1996, Kurashina et al. 1997, Otsuka et al. 
1997, Petruzzelli and Stankiewicz 2002, Kasperk et al. 2005, Ruhe et al. 2005, Schnieders et al. 
2006, Ginebra et al. 2006, Alkhraisat et al. 2010, Fullana et al. 2010, Neovius and Engstrand 
2010). The release of therapeutic drugs from CPC is dependent on several factors, including drug 
cement interaction, solubility of the drug and cement porosity. Changing these factors may result 
in a change in release kinetics of the agent (Young et al. 2008, Hofmann et al. 2009, Fullana et 
al. 2010). Release is usually coupled by a high initial burst release, followed by partial or 
complete release of the agent (Hofmann et al. 2009).  Controlling release rates can be achieved 
by incorporation of the therapeutic agent into polymeric micro-or nanoparticles.  Release of 
therapeutic agents from polymeric scaffolds such as fibers and particles have been investigated 
(Birnbaum et al. 2000, Jeon et al. 2000, Elvassore et al. 2001, Pandey et al. 2003, Salmaso et al. 
2004, Xu and Hanna 2006, Builders et al. 2008, Teply et al. 2008, Heunis et al. 2010; Heunis et 
al. 2011). The release rate depends on several polymer characteristics. Hydrophobic polymers, 
e.g. poly (lactic acid) (PLA) or poly (ε-caprolactone) polymer provides a slow release and, in 
some cases, only degrades over several months/years (Iooss et al. 2001, Salmaso et al. 2004). In 
contrast to this, a hydrophilic polymer such as poly (ethylene oxide), releases the therapeutic 
agent at a rapid rate (Kenawy et al. 2002). Co-polymers such as poly (lactide-co-glycolide) 
(PLGA) have a slower release rate and provide a more gradual release (Klose et al.2008). 
Incorporation of polymeric particles has shown to be promising in delaying release when 
incorporated into CPC (Ruhe et al. 2003, Schnieders et al. 2006). Several therapeutic agents 
have been incorporated into particles and then into cement, including gentamicin and 
recombinant human bone morphogenetic protein-2 (Ruhe et al. 2003, Schnieders et al. 2006)  
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Pathogens acquiring resistance to antibiotics is a major problem in the treatment of infections 
(Thornes et al. 2002, Pulido et al. 2008). Thornes et al. (2002) illustrated that incorporation of 
antibiotics into bone cement may also lead to increase incidence of antibiotic resistance (Thornes 
et al. 2002). Alternatives to antibiotics are therefore needed to reduce the emergence of antibiotic 
resistant pathogens (Joerger 2003). 
Bacteriocins produced by lactic acid bacteria are possible alternatives to antibiotics. These are 
small, ribosomally synthesized cationic, hydrophobic or amphiphilic peptides composed of 20-
60 amino acid residues and are divided into three classes (Class I, Class II and bacteriolysins; 
Rea et al. 2011). Bacteriocins show antimicrobial activity against closely related species and in 
several cases against antibiotic resistant microorganisms such as MRSA (methicillin resistant 
Staphylococcus aureus) and VRE (vancomycin resistant enterococci) (Van Reenen et al. 2003, 
Kruszewska et al. 2004, De Kwaadsteniet et al. 2010, Piper et al. 2010).  
The main drawback of using bacteriocins is their instability in vivo (De Kwaadsteniet et al. 2009, 
Brand et al. 2010, De Kwaadsteniet et al. 2010). Instability may be overcome by encapsulating 
the bacteriocins with biocompatible polymers. Nisin has been successfully incorporated into 
particles and showed prolonged release and activity (Salmaso et al. 2004). 
The current study aims to investigate the in vitro properties of bacteriocin-associated PLGA 
microparticles (SPM) incorporated into brushite bone cement. Peptide ST4SA produced by 
Enterococcus mundtii ST4SA was used as model peptide. 
Materials and Methods 
Materials 
Poly (D,L-lactide-co-glycolide; PLGA) lactide: glycolide 65:35 and mol wt 40 000-75 000 was 
purchased from Sigma (Sigma Aldrich, Germany). N, N-Dimethylformamide, DMF (99% min) 
was purchased from Saarchem (Saarchem, Gauteng) and ammonium Sulfate (99
.
5%) was 
acquired from Merck (Merck, Germany). The β-tri calcium phosphate (βTCP, 95%) and 
monocalcium phosphate monohydrate (MCPM, 85%) was acquired from Sigma-Aldrich (Sigma-
Aldrich, Germany). Tri-sodium citrate dihydrate was obtained from Saarchem (Saarchem, 
Gauteng, South Africa), and ammonium sulfate (99
.
5%) and Listeria Enrichment Broth (LEB) 
from Merck (Merck, Darmstadt, Germany). Dialysis membranes (1 kD, Spectra/Por
®
 6) were 
from Spectrumlabs (Spectrum Inc., CA, USA). The BCA protein assay kit was from Thermo 
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Scientific (Pierce Biotechnology, Rockford, IL, USA). All growth media used were from Biolab 
(Biolab Diagnostics, Midrand, South Africa). 
Preparation of peptide ST4SA 
E. mundtii ST4SA was cultured in 1 liter MRS broth
 
for 24 h at 30°C. Cells were harvested at 
8000 g for 10 min at
 
4°C.  The pH of the resulting supernatant was adjusted to 6∙5-7∙0 and then 
incubated at 80°C for 10 min to inactivate proteolytic enzymes. Proteins were precipitated from 
the cell-free
 
supernatant with 80% saturated ammonium sulfate (Maniatis et al. 1982). The 
precipitate
 
was collected by centrifugation (10000 g for 1 h at 4°C) and the pellet re-suspended in 
10 ml sterile distilled water. The concentrated bacteriocin was dialyzed against 4 liters sterile 
distilled water using a 1 kDa cut-off dialysis membrane. The dialyzed product was concentrated 
by freeze-drying and stored at -20°C. Antimicrobial activity
 
was determined by using the agar-
spot method (Van Staden et al. 2011). Activity
 
was expressed in arbitrary units per ml (AU ml
-1
). 
One AU is defined
 
as the reciprocal of the highest serial two-fold dilution showing
 
a clear zone 
of growth inhibition. Listeria monocytogenes EGD-e, grown in LEB supplemented with 7∙5 µg 
ml
-1
 chloramphenicol, and incubated at 37°C on a shaker, was used as sensitive strain. 
Preparation of microparticles 
Bacteriocin loaded microparticles were produced using an electrospraying method. PLGA (15% 
w/v) was dissolved in DMF containing peptide ST4SA (15 mg ml
-1
). No bacteriocin was added 
for un-associated particles (UP). A setup using a sterile tapered glass tube and high voltage 
supply was used for the production of SPM and UP (Fig. 1). The cathode was placed in the glass 
tube containing the polymer solution and anode was connected to the collector. A constant 
potential difference of 12 kV was applied to polymer solution and -5 kV to the collector (1.133 
kV/cm). The glass tube was kept at an angle of 0 to 5°. The relative humidity was kept below 
30% and the temperature at 25°C. Particles were collected and used in further experiments. 
The bacteriocin concentration in 25 mg SPM was determined by dissolving the particles in DMF. 
The protein concentration (mg ml
-1
) was determined by using the colorimetric BCA protein 
assay method at 562 nm and compared to a bovine serum albumin standard curve.  
Preparation of bone cement composites 
Cement samples were prepared according to the method described by Barralet et al. (2004). β-
TCP and MCPM were mixed in equimolar amounts with a pestle and mortar. The powder (250 
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mg) was mixed with 75∙76 µL 500 mM tri-sodium citrate (P/L ratio of 3∙3 g ml-1), which served 
as retardant. Particles were added to the powder component of the cement (10% w/w) before 
mixing with 500 mM tri-sodium citrate. Mixing was performed on a glass slab for 30 s to form a 
homogeneous paste. The paste was moulded into sterile insulin syringes, from which the tips 
have been cut off, and left to dry until hard tablets formed. The set cement cylinders were 
approx. 8 mm long and 4 mm in diameter.  
Characterization of bone cement composites and particles 
The crystal structure of the bone cement and particle morphology was studied by using scanning 
electron microscopy (SEM; Zeiss EVO MA15VP, Zeiss, Oberkochen, Germany). The cement 
cylinders were fractured and particles were sprayed onto foil, placed on an adhesive stub and 
coated with gold, before SEM analysis. Images were used to determine size distribution of 
particles using SEM Image studio software (version 10·1). 
 Powder X-ray diffraction (XRD) patterns of the set cement cylinders were recorded on a multi-
purpose diffractometer (PANalytical X‟Pert PRO, PANanyltical, Almelo, The Netherlands). 
Data were collected from 2θ = 10° - 60° with a step size of 0∙02° and a normalized count time of 
1 s/step using Cu Kaα radiation. Phase composition was checked by means of ICDD 
(international centre for diffraction data) reference patterns for β-TCP (00-009-0348), MCPM 
(01-070-0359), brushite (00-009-0077 & 01-072-0713) and hydroxyapatite (00-001-1008). XRD 
was performed on samples containing 10% w/w SPM or unloaded cement samples. 
Release studies 
All release studies were carried out in PBS buffer (pH 7∙4) at 37°C and agitation; 25 mg SPM 
were added to 1 ml buffer and incubated for several hours. Particles were spun down at 8000 g 
for 1 min to avoid accidental removal. Removed buffer was replaced with fresh buffer and 
incubated again. Cement samples were prepared as previously described and incubated in 5∙0 ml 
PBS buffer for release studies, un-dissolved particles were harvested at 8000 g for 1 min. Protein 
concentration (mg ml
-1
) in the particle-free buffer was determined by using the colorimetric BCA 
protein assay method at 562 nm and the concentration determined by using a bovine serum 
albumin standard curve.  
Activity of particles and cement composites 
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Particles were scattered over an LEB agar (1∙0% w/w) plate seeded with L. monocytogenes 
EGD-e and incubated at 37°C 24 h. Brushite-SPM or -UP composites were placed into LEB agar 
(1∙0% w/w) plate seeded with L. monocytogenes EGD-e and incubated at 37°C 24 h. Observation 
of clear zones around samples was indicative of antimicrobial activity. 
Calculations and analysis of data 
Data were collected in Microsoft Excel 2007. Data points indicated with standard deviations; 
represent an average of three repeats. The rate of bacteriocin release is presented as the 2-point 
moving average. Student‟s t test was used to compare release curves. 
Results  
The average bacteriocin concentration in 25 mg SPM was 3∙73 mg ml-1 (±0∙63). Electrosprayed 
UP had sizes ranging from 1014 nm to 1992 nm (Fig. 2), with an average of 1101∙51 nm 
(±179∙1). Particles sprayed with bacteriocin had sizes ranging from 330 nm to 2520 nm (Fig. 3), 
with an average size of 1048∙4 nm (±322). Incorporation of the SPM into the cement did not 
result in significant structural changes (Fig. 4 A and B). Particles could, however, be visualised 
imbedded in the cement (Fig. 4B). XRD patterns of control cement and brushite-SPM 
composites compared well with each other (Fig. 5). The diffraction patterns also corresponded 
well to that of brushite (ICDD 00-009-0077 & 01-072-0713). Bacteriocin was released from 
SPM over a period of 240 h (Fig. 6). After the first 12 h, 36∙5% (± 1∙43) of the total bacteriocin 
associated with the particles was released, followed by a 1∙6% (±0∙18) release over the next 228 
h. Brushite-SPM composites had a significant reduction in burst release of the bacteriocin in the 
first 12 h (p<0∙001; Fig. 6) compared with SPM not incorporated. Within the first 12h 23∙2% 
(±1∙21) was released from the brushite-SPM composites, followed by a 7∙9% (±1.8) release up to 
240 h. Particle and brushite-SPM composites released active bacteriocin and inhibited the growth 
of L. monocytogenes EGD-e (Fig. 7). 
Discussion 
Electrospraying was used to produce particles in the submicron range; SPM had a wider size 
distribution than UP. The wider range in size distributions seen in SPM may be due to variations 
in conductivity and viscosity of the bacteriocin polymer solution (Morota et al. 2004, Xu and 
Hanna 2006). Addition of SPM to cement did not have a significant effect on the setting reaction 
or entanglement of crystals, as shown with XRD and SEM analysis. Similar results have been 
obtained with the addition of PLGA and other microparticles to CPC (Schnieders et al. 2006, 
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Fullana et al. 2010). Low concentrations of bacteriocin were released from PLGA micro 
particles (i.e. 38∙1% ±1∙5). Salmaso et al. (2004) also reported a low release for nisin A from 
PLA particles. However, they found that the nisin A released from particles inhibited the growth 
of a sensitive strain for up to 40 days in broth (Salmaso et al. 2004). Bacteriocins can be released 
at small concentrations over longer periods of time thus they are very potent and can be active at 
picomolar concentrations (Morgan et al. 2005, Nissen-Meyer et al. 2009). Release of bacteriocin 
from particles was with an initial burst in the first 12 h. After addition of SPM to the cement a 
more gradual initial release was noted, followed by a steady release of bacteriocin. Schnieders et 
al. (2006) reported a similar result with the addition of gentamicin-loaded PLGA particles into 
CPC. Addition of the particles to the cement significantly reduced burst release (Schnieders et al. 
2006). This can be attributed to a combination of embedding of SPM in the cement matrix, 
polymer degradation (depended on buffer contact) and interaction between the bacteriocin and 
cement. The properties of PLGA may also contribute to the slow release profiles. In PLGA lactic 
acid and glycolic acid are chemically bound together as a result ester bonds need to be 
hydrolysed for PLGA to be degraded (Nijenhuis et al. 1996; Wu and Wang 2001). Lactic acid is 
more hydrophobic than glycolic acid therefore lactide rich PLGA degrades more slowly resulting 
in delayed release kinetics (Nijenhuis et al. 1996; Wu and Wang 2001). All of these factors 
influence release kinetics of the bacteriocin from the particles and cement (Schnieders et al. 
2006). The release of unloaded peptide ST4SA is associated with a high burst release with more 
than 80% of peptide ST4SA released (van Staden et al. 2011). Reducing the release of 
therapeutic agents may be advantageous for prolonged activity and protection from degrading 
substances (i.e. proteases). Bacteriocin released from the particles and the brushite-SPM 
composites inhibited the growth of L. monocytogenes EGD-e, indicating that biological activity 
was retained. Heunis et al. (2010) reported a decrease in activity of plantaricin 423 after 
electrospinning into fibers. However Xie and Wang (2007) found that after electrospraying BSA 
retained its secondary structure and was not degraded after prolonged release, suggesting that the 
technique does not significantly influence protein structure (Xie and Wang 2007). They also 
reported a high retention of lysozyme bioactivity of 92% (Xie and Wang 2007). The effect of 
electrospraying on the activity of peptide ST4SA needs to be determined.      
In conclusion, peptide ST4SA was electrosprayed in association with PLGA to form submicron 
particles. The particles released active bacteriocin at a delayed rate and incorporation of the SPM 
into brushite bone cement resulted in a decrease in initial burst release. The results reported here 
suggest that it is possible to associate bacteriocins with a polymer to form submicron PLGA 
particles using electrospraying and produce brushite-SPM composites.    
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Figure 1 Diagram of the electrospraying setup used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
91 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
P
e
rc
e
n
ta
ge
 p
ar
ti
cl
e
s 
Size (nm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Scanning electron microscope (SEM) images of UP The scale bar represents 2 µm 
(image captured at 5000 times magnification). Graph represents size distribution of UP 
according to analysis with SEM Image studio.  
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Figure 3 SEM images of SPM. The scale bar represents 2 µm (image captured at 5000 times 
magnification). Graph represents size distribution of SPM according to analysis with SEM Image 
studio. 
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Figure 4 SEM images of brushite cement samples without SPM (A) and cement samples 
containing 10% w/w, SPM (B).  The scale bar represents 2 µm (image captured at 5000 times 
magnification). 
A 
B 
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Figure 5 XRD patterns of unloaded (control) cement samples and brushite-SPM composites 
(PLGA-ST4 cement). The red lines indicates the main brushite peaks (ICDD 00-009-0077). 
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Figure 6 Cumulative release of peptide ST4SA from SPM ( ) and brushite-SPM composites (
), expressed as percentage of original protein content. 
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Figure 7 Soft agar (1% w/w) plates seeded with Listeria monocytogenes EGD-e, scattered SPM 
(A) and UP (B). Imbeded with brushite-SPM composites (C) and brushite-UP composites (D). 
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Abstract 
 
Aims: To determine if nisin F-loaded self-setting brushite cement could control the growth of 
Staphylococcus aureus in vivo. 
Methods and Results: Brushite cement was prepared by mixing equimolar concentrations of β-
tricalcium phosphate and monocalcium phosphate monohydrate. Nisin F was added at 5.0%, 
2.5% and 1.0% (w/w) and the cement moulded into cylinders. In vitro antibacterial activity was 
determined using a delayed agar diffusion assay. Release of nisin F from the cement was 
determined using BCA protein assays. Based on scanning electron microscopy and X-ray 
diffraction analysis, nisin F did not cause significant changes in cement structure or chemistry. 
Cement containing 5.0% (w/w) nisin F yielded the most promising in vitro results. Nisin F-
loaded cement was implanted into a subcutaneous pocket on the back of mice and then infected 
with S. aureus Xen 36. Infection was monitored for 7 days, using an in vivo imaging system. 
Nisin F prevented S. aureus infection for 7 days and no viable cells were isolated from the 
implants. 
Conclusions: Nisin F-loaded brushite cement successfully prevented in vivo growth of S. 
aureus. 
Significance and Impact of the Study: Nisin F incorporated into bone cement may be used to 
control S. aureus infection in vivo. 
 
Keywords 
Nisin F, brushite, bone cement, in vivo activity, S. aureus growth inhibition 
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Introduction 
Bacterial infection is one of the major complications in orthopedic surgery and may lead to 
permanent damage of tissue or bone (Krishnan et al. 1993; Fialkov et al. 2001; Cosgrove and 
Carmeli 2003).  Antibiotics orally or intravenously administered are often ineffective, due to 
poor penetration of infected sites (Frommelt and Kühn 2005; Zimmerli 2006).  Furthermore, 
biofilms that form on implants may also prevent the migration of immune cells to infected areas 
(Stewart and Costerton 2001).  Antibiotic-loaded bone cement may be a solution to the control of 
orthopedic related bacterial infections (Jiranek et al. 2006). 
Polymethylmethacrylate (PMMA) antibiotic-loaded bone cements have been used in orthopedic 
surgery (Van de Belt et al. 2001).  Antibiotic-loaded bone cement can lower the rate of infection 
by 50% in primary hip arthoplasty and with 40% in revision hip arthoplasty of previously 
infected implants (Parvizi et al. 2008). PMMA bone cements are however not bioresorbable.  
Calcium phosphate bone cement (CPC) has excellent bioactivity, bioresorbability and 
biocompatibility properties and is considered more practical than PMMA by some researchers 
(Ruhe et al. 2005; Ginebra et al. 2006b; Schnieders et al. 2006; Zhang et al. 2008; Alkhraisat et 
al. 2009, Hofmann et al. 2009; Alkhraisat et al. 2010; Fullana et al. 2010).  CPC can easily be 
molded to defects as well as be injected, and sets in situ (Ginebra et al. 2006a).  In addition to 
these properties, CPC sets at low temperatures, which allows the incorporation of heat sensitive 
drugs or proteins (Bohner 2000).  Antibiotic-loaded CPC proved effective in the control of in 
vivo infections (Hamanishi et al. 1996; Otsuka et al. 1997; Stallmann et al. 2004; Joosten et al. 
2005; Ginebra et al. 2006b).  However, CPC has a low mechanical strength and can only be used 
in non- or low load-bearing areas (Ginebra et al. 2006a). 
The frequent use of antibiotic-loaded bone cement may increase the chances of developing 
antibiotic-resistant strains (Thornes et al. 2002).  Bacteriocins may offer an alternative to 
conventional antibiotics; these are small cationic or amphiphilic antimicrobial peptides that 
inhibit the growth of closely related species (Cotter et al. 2005).  A few bacteriocins, including 
nisin, have been described with activity against methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant enterococci (VRE) (Piper et al. 2010).  Nisin binds to lipid-II 
on bacterial cell walls and inserts into the cell membrane to form pores, resulting in the efflux of 
intracellular material and dissipation of the proton motive force (Hsu et al. 2004; Bauer and 
Dicks 2005). 
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In the current study we determine the antibacterial activity of nisin F incorporated into brushite 
bone cement.  In vivo studies were conducted on mice that have been infected with a 
bioluminescent strain of S. aureus.  Changes in infection were recorded by monitoring changes 
in bioluminescence. 
Materials and methods  
Monocalcium phosphate monohydrate (MCPM, 85%) and β-tri calcium phosphate (βTCP, 95%) 
were purchased from Sigma-Aldrich (Sigma-Aldrich, Steinheim, Germany).  Tri-sodium citrate 
dihydrate was purchased from Saarchem (Saarchem, Gauteng, South Africa), and ammonium 
sulfate (99.5%) from Merck (Merck, Darmstadt, Germany).  Dialysis membranes (1 kD, 
Spectra/Por® 6) were purchased from Spectrumlabs (Spectrum Inc., CA, USA). Backlight
TM
 
LIVE/DEAD bacterial viability kits (L7012) were from Invitrogen (Invitrogen, Leiden, The 
Neterlands). All growth media used were from Biolab (Biolab Diagnostics, Midrand, South 
Africa). 
Preparation of nisin F 
Lactococcus lactis subsp. lactis F10 (De Kwaadsteniet et al. 2008) was cultured in 1 litre De 
Man Rogosa and Sharpe (MRS) broth for 24 h at 30°C.  Cells were harvested at 8000 g for 15 
min at 4°C.  The pH of the cell-free supernatant was adjusted to 6.5 to 7.0 and then treated at 
80°C for 10 min to inactivate proteolytic enzymes.  Proteins were precipitated from the cell-free
 
supernatant with 80% saturated ammonium sulphate (Maniatis et al. 1982).  The precipitate
 
was 
collected by centrifugation at 10000 g for 1 h at 4°C and the pellet re-suspended in 10 ml sterile 
distilled water.  The suspension containing the lantibiotic was dialyzed against 4 litres sterile 
distilled water using a 1 kDa cut-off dialysis membrane.  The dialyzed product was concentrated 
by freeze-drying, resulting in semi-purified nisin F and stored at -80°C.  Antimicrobial activity
 
was determined by using the agar-spot method (Knoetze et al. 2008).  Activity
 
was expressed in 
arbitrary units per ml (AU ml
-1
).  One AU is defined
 
as the reciprocal of the highest serial two-
fold dilution showing
 
a clear zone of growth inhibition.  S. aureus Xen 36, grown in Brain Heart 
Infusion (BHI) broth or BHI soft agar (1∙0%, w/v, agar), supplemented with 200 µg ml-1 
kanamycin, was used as sensitive strain.  Incubation was at 37°C for 24 h. 
Preparation of bone cement containing nisin F 
Bone cement samples were prepared according to the method described by Barralet et al. (2004).  
Equimolar amounts of βTCP and MCPM were mixed using a pestle and mortar.  Freeze-dried 
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nisin F was added to 250 mg dry cement powder to yield final concentrations of 5.0%, 2.5% and 
1.0% (w/w), respectively.  The same quantity of freeze-dried nisin F was suspended in sterile 
distilled water and activity determined by using the agar-spot method as described before.  Tri-
sodium citrate (75.76 µl of 500 mM; P/L ratio of 3.3 g ml
-1
) was added to the cement powder to 
slow down setting.  Mixing to a homogeneous paste was done on a glass slab for 30 s.  The paste 
was moulded into sterile disposable insulin syringes, of which the tips have been cut off, and left 
to set.  The set bone cement cylinders were approx. 8 mm long and 4 mm in diameter. 
Structural analysis of bone cement 
Powder X-ray diffraction (XRD) patterns of the set bone cement cylinders were recorded on a 
multi-purpose diffractometer (PANalytical X‟Pert PRO, PANanyltical, Almelo, The 
Netherlands).  Data were collected from 2θ = 10° to 60° with a step size of 0.02° and a 
normalized count time of 1 s step
-1
 using Cu Kaα radiation.  Phase composition was checked by 
means of ICDD (international centre for diffraction data) reference patterns for β-TCP (00-009-
0348), MCPM (01-070-0359), brushite (00-009-0077 and 01-072-0713) and hydroxyapatite (00-
001-1008).  The crystal structure of the bone cement was studied using a scanning electron 
microscope (SEM; Zeiss EVO MA15VP, Zeiss, Oberkochen, Germany).  The bone cement 
cylinders were fractured and placed on an adhesive stub and sputter-gold coated before analysis. 
Images were taken at 5000 times magnification at 7.00 kV and a working distance of 10 mm. 
In vitro antimicrobial activity and release of nisin F from bone cement 
The activity of nisin F incorporated into bone cement was studied using a delayed agar-diffusion 
method (Bayston and Milner 1982).  Bone cement cylinders containing the three different 
concentrations of nisin F were each covered with 20 ml BHI soft agar (1.0%, w/v, agar) that has 
been seeded with 1∙0 ml S. aureus Xen 36 (1∙0 x 107 CFU ml-1) and then incubated at 37°C for 
24h.  Antimicrobial activity was recorded by measuring the diameter of the growth inhibition 
zone through the centre of the bone cement cylinder.  The cylinders were then aseptically 
removed, placed into a fresh plate of soft agar seeded with S. aureus Xen 36 (1∙0 x 107 CFU ml-
1
) and incubated at 37°C for 24h.  Transfer of the cylinders from one plate to the other was 
repeated until no growth inhibition was observed. 
In another experiment, washed cells of S. aureus Xen 36 (1∙0 x 108 CFU ml-1) were stained with 
the Backlight
TM
 LIVE/DEAD fluorescent probes SYTO 9 (emits green when excited with 472 
nm) and propidium iodide (emits red when excited with 572 nm), according to the 
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manufacturer‟s instructions.    S. aureus Xen 36 (1∙0 x 107 100 µl-1) was added to 20 mg bone 
cement, supplemented with 5.0% (w/w), 2.5% (w/w) and 1.0% (w/w) nisin F, respectively, and 
incubated for 60 min at 37°C.  Bone cement without nisin F served as control.  At 5∙0, 30 and 60 
min, samples were exposed to 472 nm and 572 nm, using a Xenon-Arc burner (Olympus 
Biosystems GmbH, Germany).  Fluorescence was recorded using an inverted fluorescence 
microscope fitted with an Olympus Cell^R system attached to an IX-81 (Olympus Biosystems 
GmbH, Hamburg, Germany).  Images were taken with a F-view-II cooled CCD camera (Soft 
Imaging Systems, Hamburg, Germany).  Emission was collected using a UBG triple- bandpass 
emission filter cube.  For the z-stack image frame acquisition, an Olympus Plan Apo N 60x/1∙4 
Oil objective and the Cell^R imaging software were used.  Images were processed, background-
subtracted, and expressed as maximum intensity projection.  
The rate at which nisin F diffused from the bone cement cylinders was estimated from the 
rate at which proteins were released.  Bone cement cylinders containing 5.0% (w/w) nisin F were 
incubated in 5∙0 ml Phosphate Buffered Saline (PBS) buffer (pH 7.4) at 37°C and slowly stirred.  
At selected time intervals the entire volume of buffer was collected and centrifuged at 8000 g for 
1∙0 min to remove non-dissolved particles.  The protein concentration (mg ml-1) in the 
supernatant was determined by using the colorimetric BCA protein assay method at 562 nm.  
Readings were recorded from standard curves prepared with bovine serum albumin.  Buffer 
extracted was replaced with fresh buffer and the cylinders incubated until the next reading.  
Readings were recorded over 120 h.  Release of protein from the bone cement cylinders was 
expressed as percentage of the protein content originally present in the sample. In another 
experiment, samples were incubated in PBS buffer (pH 7.4) for 24 h after which antimicrobial 
activity of released nisin F, in the PBS buffer, was tested against S. aureus Xen 36 seeded in BHI 
soft agar.  
Hemolytic activity of nisin F bone cement 
The hemolytic activity of nisin F-loaded bone cement was determined spectrophotometrically 
using a hemoglobin release assay.  Sheep erythrocytes were collected by centrifugation at 800 g 
for 10 min and washed three times with PBS (pH 7∙0; 10 min at 800 g).  Diluted (10x in PBS) 
red blood cells (RBC; 200 µl) were added to 20 mg bone cement samples with 5∙0% (w/w) nisin 
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F and without nisin F.  Samples were incubated at 37°C for 1∙0 h. Aliquots (100 µl) were 
removed from samples and centrifuged at 4000 g for 10 min.  Supernatants (50 µl) were 
collected and read spectrophotometrically at 541 nm to determine hemoglobin release.  Zero and 
100% hemolysis was determined using PBS (pH 7∙0) and 0∙1% Triton X100, respectively.  
Insertion of bone cement cylinders into mice 
Experiments on animals have been approved by the Ethics Committee of the University of 
Stellenbosch (ethics reference number: 11NM_DIC01). Male mice (BALB/c), weighing between 
20 and 30 g, were fed a standard rodent diet and kept under controlled environmental conditions 
(12 h light-dark cycles, 20-22˚C). 
Twenty-four mice (six per group) were anaesthetized via inhalation with 2.0% (v/v) isoflurane 
(Isofor, Safe Saline pharmaceuticals, Florida, South Africa).  The back of each mouse was 
shaved and disinfected with Betadine (10%, v/v).  A mid-scapular incision, approx. 1∙0 cm in 
length, was made and the bone cement cylinder inserted into the subcutaneous pocket.  Bone 
cement implanted in mice of groups 1 and 3 did not contain nisin F, whereas the implants used in 
groups 2 and 4 contained 5∙0% (w/w) nisin F.  The subcutaneous pockets of mice in groups 3 
and 4 were infected with 100 µl S. aureus Xen 36 (1∙0 x 103 CFU 100 µl-1), whereas 100 µl 
sterile saline was injected in the subcutaneous pockets of the control mice (groups 1 and 2).  
Incisions were closed using CliniSut 1.5 (4/0) sutures (Akacia health, Port Elizabeth, South 
Africa) and dabbed with 10% (v/v) Betadine.  Pain was controlled by injecting the mice with 
bupronorphine (0.03 mg kg
-1
 bodyweight; Temgesic, Schering-Plough (Pty) Ltd., Woodmead, 
South Africa) directly after surgery and 24 h later. 
Evaluation of in vivo infection 
S. aureus infections were recorded using the Xenogen in vivo bioluminescent imaging system 
(Xenogen IVIS
®
, Caliper Life Sciences, Hopkinton, MA, USA).  Images were recorded directly 
after closing of the subcutaneous pocket and every 24 h thereafter for 7 days.  Readings are 
expressed as average radiance (photons cm
-2
 second
-1
 steridian
-1
) within a circular region of 
interest (1∙0 x 103 pixels) and calculated by using Living Image® software (Bernthal et al. 2010; 
Caliper Life Sciences).  After 7 days of observation the animals were killed with an overdose of 
pentabarbitione sodium (Euthapent, Kyron Laboratories (Pty) Ltd., Benrose, South Africa) and 
the bone cement cylinders removed.  Swabs were taken from the subcutaneous pockets and 
streaked onto BHI agar supplemented with 200 µg ml
-1
 kanamycin.  The bone cement implants 
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were vigorously vortexed in 1∙0 ml sterile saline for 5∙0 min.  The suspensions were serially 
diluted and plated out onto the same growth medium.  All plates were incubated at 37°C for 24 
h. Blood were collected one day before surgery and on days 0, 4 and 5 form selected mice in 
group 1 and 2 (n=6) for preliminary analysis of total and differential leukocyte counts. 
Statistical analysis 
All experiments were conducted in triplicate, unless otherwise stated.  Standard deviation was 
calculated using Student‟s t-test (two-tailed) with p < 0.05, p < 0.01 and p < 0.001 considered as 
significant. 
Results 
Activity of nisin F 
Freeze-dried nisin F suspended in sterile distilled water at 5.0%, 2.5% and 1.0% (w/v) yielded an 
activity of 6,400, 3,200 and 1,280 AU ml
-1
, respectively. Thus, the activity of nisin F in the bone 
cement cylinders (250 mg) corresponded to 6,400 AU, 3,200 AU and 1,280 AU. 
Structural analysis of bone cement 
The XRD patterns showed minor peaks for βTCP and MCPM in the bone cement cylinders, with 
and without nisin F (Fig. 1 A and B).  The patterns for samples with and without nisin F 
corresponded well with the ICCD pattern of brushite and did not indicate significant changes 
with the addition of nisin F.  SEM images of fractured bone cement cylinders, with and without 
nisin F (5∙0% w/w) showed densely packed plates and blocks of brushite as well as clusters of 
smaller particles (Fig. 1 A and B). This indicates that the addition of nisin F did not interfere 
with crystal entanglement and therefore crystal structure. 
In vitro antimicrobial activity and release of nisin F from bone cement 
All nisin F-loaded bone cement samples (6,400 AU, 3,200 AU or 1,280 AU) released active 
nisin F. Samples containing 6,400 AU and 3,200 AU nisin F clearly inhibited the growth of S. 
aureus Xen 36 on agar plates for at least 72 h (Fig. 2). There was no statistical difference in the 
activity between bone cement samples containing 6,400 AU and 3,200 AU nisin F (p > 0.05), 
except after 24 h (p < 0.05). Samples incorporated with 1,280 AU nisin F inhibited the growth of 
S. aureus Xen 36 for only 48 h. There was an increase in inhibition zone size in samples 
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containing nisin F 6,400 AU from 24 h to 48 h, however this was not statistically significant (p > 
0∙05). 
A few membrane compromised bacteria were observed in bone cement without nisin F.  
However, in the presence of all nisin F-loaded bone cement formulations the majority of bacteria 
showed signs of membrane damage (stained red) after 30 min (Fig. 3). Most of the nisin F 
samples (containing 6,400 AU) was released from bone cement into PBS buffer (pH 7.4) during 
the first 12 h (Fig. 4; 71∙7 % ±0∙81). This was followed by a steady release of 4∙98 % (±0∙81) 
over the next 108 h. Release studies were only done on samples containing 6,400 AU. PBS 
buffer (pH 7.4), containing released nisin F from samples incubated for 24 h, retained activity 
against S. aureus Xen 36 seeded in BHI soft agar. 
Hemolytic activity of nisin F bone cement 
Nisin F-loaded samples showed minimal hemolysis, with 9∙28 % (±2∙08) relative hemolysis as 
compared to 0∙1 % v/v Triton X100 after 1∙0 h incubation at 37°C. 
In vivo activity of nisin F incorporated into bone cement 
No bioluminescent cells of S. aureus Xen 36 were recorded in mice of groups 1 and 2 which 
were the uninfected control groups (Fig. 5). Mice implanted with nisin F-loaded (5∙0% w/w) 
bone cement do not indicate any bioluminescent signals (group 4; Fig. 5) Bioluminescent cells 
were, however, recorded in mice of group 3 (bone cement implant without nisin F and infected 
with S. aureus Xen 36), from day one throughout the 7 day trial (Fig. 5).  Implants collected 
from group 3 had high bacterial cell numbers associated with implants (2.3 x 10
7
 CFU ml
-1
) and 
S. aureus were isolated from the swabs.  No viable cells were isolated from bone cement 
implants and wound swabs collected from mice in groups 1, 2 and 4. Preliminary blood analysis 
of mice in group 1 and 2 indicate that total and differential leukocyte counts did not undergo any 
significant changes in either total or subpopulation counts (not shown). 
Discussion 
Incorporation of nisin F into the bone cement did not interfere with the setting reaction or crystal 
entanglement of the cement. The incorporation of bacteriocin ST4SA into the same cement 
reported similar results (Van Staden et al. 2011). The residual levels of βTCP and MCPM are 
possibly due to un-reacted starting material and correlates with results reported for other 
therapeutic agents incorporated into bone cement (Bohner et al. 1997, Le Nihouannen et al. 
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2008, Tamimi et al. 2008). Nisin F was released in its active form from brushite bone cement 
and inhibited S. aureus growth, similar to results for bone cement loaded with bacteriocin 
ST4SA. Brushite bone cement sets at about 37°C and pH < 6∙0 which provides a more favorable 
environment for the bacteriocin.  
The steady decline in antimicrobial activity recorded over 72 h suggests that nisin F slowly 
diffused from the bone cement.  At lower levels (1,280 AU per cylinder), the residual 
concentration of nisin F was too low to inhibit the growth of S. aureus Xen 36 for longer than 48 
h.  Release of antimicrobial agents from bone cement is influenced by a number of factors, e.g. 
solubility, interaction with cement particles and porosity of the bone cement (Ginebra et al. 
2006a, Hofmann et al. 2009, Tamimi et al. 2009). Release of nisin F from bone cement is most 
likely dose dependent, as observed when higher concentrations were incorporated into bone 
cement and tested against S. aureus Xen 36. Bacteriocins are very potent at low concentrations 
and are able to dissipate the proton motive force of cell membranes within a few minutes 
(Winkowski et al. 1994). The fluorescent microscopy results illustrate the antimicrobial potency 
of nisin F, in killing the bacterial cells upon contact. Similar to results reported for other 
therapeutic agents, a high burst release of nisin F was observed in the first 12 h. (Bohner et al. 
1997; Tamimi et al. 2008; Young et al. 2008; Hofmann et al. 2009; Fullana et al. 2010) and 
bacteriocin ST4SA (Van Staden et al. 2011).  
Three concentrations of nisin F were evaluated in vitro to determine the optimal concentration 
for use in in vivo studies. From the in vitro results and preliminary in vivo trials (data not shown) 
it was seen that samples containing 6,400 AU nisin F most effectively inhibited S. aureus. 
Bioluminescent imaging has been used in a number of antimicrobial studies (Brand et al. 2010, 
De Kwaadsteniet et al. 2010) and proved effective in studying antimicrobial implants in mice 
(Bernthal et al. 2010).  Nisin F incorporated (6,400 AU) in bone cement controlled S. aureus 
infection for 7 days. Infection in group 3 (infected control) could only be visualized with 
bioluminescence from day 1 onwards. This is most likely due to a combination of insufficient 
bacterial numbers present at day 0 and absorption of bioluminescent signal by animal tissue 
(Doyle et al. 2004). Brand et al. (2010) has shown that nisin F, intraperitoneally injected into 
mice, could control the growth of S. aureus, although for only 15 min, based on changes 
recorded in bioluminescence.  The inability to suppress S. aureus over a longer period has been 
attributed to the rapid degradation of nisin F by proteolytic enzymes (Brand et al. 2010), or 
possibly non-specific binding of the peptide. 
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In another study, nisin F inhibited the growth of S. aureus in the respiratory tract of immune-
compromised rats when administered through the nasal cavity (De Kwaadsteniet et al. 2009).  
Attempts to treat subcutaneous S. aureus infections with nisin F, on the other hand, were 
unsuccessful (De Kwaadsteniet et al. 2010).  The reason for this has also been attributed to 
possible degradation of the peptide (De Kwaadsteniet et al. 2010).  However, intravenous 
Teflon® catheters, which have been coated with nisin, implanted into the jugular veins of sheep 
have shown antimicrobial activity for more than 5 h (Bower et al. 2002).  
Incorporation of nisin F into bone cement may facilitate controlled release of the peptide, and 
most probably delays the rate at which the peptide is degraded. Nisin used as a prophylactic 
seems to more effective than treatment of bacterial infections. This can be seen here as well as in 
several other studies (Ghiselli et al. 2004, De Kwaadsteniet et al. 2009, Brand et al. 2010, De 
Kwaadsteniet et al. 2010). 
Hemolysis release assays can be used to study preliminary cytotoxicity of therapeutic agents 
(Maher and McClean 2006).  Nisin has showed low toxicity against RBC which makes it a 
possible candidate for use in systemic infections (Maher and McClean 2006).  Bower et al. 
(2002) also reported no reaction to implanted materials coated with nisin when implanted in vivo.  
Preliminary analysis of blood collected substantiates the hemolysis assay results with no 
significant changes observed in either total or subpopulation leukocyte counts of uninfected 
groups. 
The prophylactic use of antimicrobial-loaded bone cement may result in the prevention of 
infection. However increase antibiotic-resistance has been reported in vivo with the use of 
antibiotic-loaded bone cement (Thornes et al. 2002).  Nisin F may be an effective alternative to 
antibiotics.  Of all nisin variants, nisin F showed the most promising results in vitro against 
MRSA and VRE (Piper et al. 2010).  As with any antimicrobial the risk of the target organism 
acquiring resistance is still a possibility (Neu 1992, Crandall and Montville 1998, Walsh 2003, 
Kramer et al. 2004).  Due to different mechanisms it may be beneficial to combine antibiotics 
and bacteriocins or two different peptides to reduce the risk of developing resistance (Brumfitt et 
al. 2002, Ghiselli et al. 2004, Naghmouchi et al. 2010). 
The current study evaluated the effectiveness of nisin F-loaded brushite bone cement in vitro and 
in vivo. We have shown that S. aureus infection could be controlled for 7 days.  Furthermore, 
nisin F implants that were removed did not show signs of contamination, compared with 
untreated implants.  The results suggest the possible use of nisin F in bone cement implants. 
Stellenbosch University  http://scholar.sun.ac.za
109 
 
 
Acknowledgements 
The project was funded by CiplaMedpro Ltd (Pty), South Africa, and the National Research 
Foundation, South Africa.  The authors would like to thank Dr. Benjamin Loos (Department of 
Physiological Sciences, Stellenbosch University, South Africa) for technical advice and 
fluorescent imaging and Mr. Noël Markgraaff (Department Physiological Sciences, Stellenbosch 
University) for assistance with animal operations. 
Stellenbosch University  http://scholar.sun.ac.za
110 
 
 
References  
Alkhraisat, M.H., Rueda, C., Cabrejos-Azama, J., Lucas-Aparicio, J., Mariño, F.T., García-
Denche, J.T., Jerez, L.B., Gbureck, U. and Cabarcos, E.L. (2010) Loading and release of 
doxycycline hyclate from strontium-substituted calcium phosphate cement. Acta Biomater 6, 
1522-1528.  
Alkhraisat, M.H., Rueda, C., Marino, F.T., Torres, J., Jerez, L.B., Gbureck, U. and Cabarcos, 
E.L. (2009) The effect of hyaluronic acid on brushite cement cohesion. Acta Biomater 5, 3150-
3156.  
Barralet, J., Grover, L. and Gbureck, U. (2004) Ionic modification of calcium phosphate cement 
viscosity. Part II: hypodermic injection and strength improvement of brushite cement. Biomater 
25, 2197-2203.  
Bauer, R. and Dicks, L.M.T. (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food 
Microbiol 101, 201-216.  
Bayston, R. and Milner, R. (1982) The sustained release of antimicrobial drugs from bone 
cement. An appraisal of laboratory investigations and their significance. J Bone Joint Surg (Br) 
64, 460-464.  
Bernthal, N.M., Stavrakis, A.I., Billi, F., Cho, J.S., Kremen, T.J., Simon, S.I., Cheung, A.L., 
Finerman, G.A., Lieberman, J.R. and Adams, J.S. (2010) A mouse model of post-arthroplasty 
Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant 
coatings. PLoS One 5, 10.1371/journal.pone.0012580 [DOI].  
Bohner, M. (2000) Calcium orthophosphates in medicine: from ceramics to calcium phosphate 
cements. Inj 31, 37-47.  
Bohner, M., Lemaître, J., Van Landuyt, P., Zambelli, P.Y., Merkle, H.P. and Gander, B. (1997) 
Gentamicin-loaded hydraulic calcium phosphate bone cement as antibiotic delivery system. J 
Pharm Sci 86, 565-572.  
Bower, C., Parker, J., Higgins, A., Oest, M., Wilson, J., Valentine, B., Bothwell, M. and 
McGuire, J. (2002) Protein antimicrobial barriers to bacterial adhesion: In vitro and in vivo 
evaluation of nisin-treated implantable materials. Colloid Surf B: Biointer 25, 81-90.  
Stellenbosch University  http://scholar.sun.ac.za
111 
 
 
Brand, A.M., De Kwaadsteniet, M. and Dicks, L.M.T. (2010) The ability of nisin F to control 
Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett Appl Microbiol 
51, 645-649.  
Brumfitt, W., Salton, M. and Hamilton-Miller, J. (2002) Nisin, alone and combined with 
peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus 
aureus and vancomycin-resistant enterococci. J Antimicrob Chemother 50, 731-734.  
Cosgrove, S.E. and Carmeli, Y. (2003) The impact of antimicrobial resistance on health and 
economic outcomes. Clin Infect Dis 36, 1433-1437.  
Cotter, P.D., Hill, C. and Ross, R.P. (2005) Bacteriocins: developing innate immunity for food. 
Nat Rev Microbiol 3, 777-788.  
Crandall, A.D. and Montville, T.J. (1998) Nisin resistance in Listeria monocytogenes ATCC 
700302 is a complex phenotype. Appl Environ Microbiol 64, 231-237.  
De Kwaadsteniet, M., Ten Doeschate, K. and Dicks, L.M. (2008) Characterization of the 
structural gene encoding nisin F, a new lantibiotic produced by Lactococcus lactis subsp. lactis 
isolated from fresh water catfish (Clarias gariepinus). Appl Environ Microbiol 74, 547–549. 
De Kwaadsteniet, M., Doeschate, K. and Dicks, L.M.T. (2009) Nisin F in the treatment of 
respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol 48, 65-70.  
De Kwaadsteniet, M., Van Reenen, C. and Dicks, L.M.T. (2010) Evaluation of nisin F in the 
treatment of subcutaneous skin infections, as monitored by using a bioluminescent strain of 
Staphylococcus aureus. Prob Antimicrob Prot 2, 61-65.  
Doyle, T.C., Burns, S.M.  and Contag, C.H. (2004). In vivo bioluminescence imaging for 
integrated studies of infection. Cell Microbiol 6, 303-317.  
Fialkov, J.A., Holy, C., Forrest, C.R., Phillips, J.H. and Antonyshyn, O.M. (2001) Postoperative 
infections in craniofacial reconstructive procedures. J Craniofac Surg 12, 362-368.  
Frommelt, L. and Kühn, K.D. (2005) Properties of bone cements: Antibiotic-loaded bone 
cements. In The well cemented total hip arthoplasty: Theory and practice ed. Breusch, S.J. and 
Malchau, H. pp. 86-92. Germany: Springer Medizin Verlag.  
Stellenbosch University  http://scholar.sun.ac.za
112 
 
 
Fullana, G., Ternet, H., Freche, M., Lacout, J.L. and Rodriguez, F. (2010) Controlled release 
properties and final macroporosity of a pectin microspheres–calcium phosphate composite bone 
cement. Acta Biomater 6, 2294-2300.  
Ghiselli, R., Giacometti, A., Cirioni, O., Dell'Acqua, G., Mocchegiani, F., Orlando, F., D'Amato, 
G., Rocchi, M., Scalise, G. and Saba, V. (2004) RNAIII-inhibiting peptide and/or nisin inhibit 
experimental vascular graft infection with methicillin-susceptible and methicillin-resistant 
Staphylococcus epidermidis. EurJ Vasc endovasc surg 27, 603-607.  
Ginebra, M.P., Traykova, T. and Planell, J.A. (2006a) Calcium phosphate cements: Competitive 
drug carriers for the musculoskeletal system? Biomater 27, 2171-2177.  
Ginebra, M.P., Traykova, T. and Planell, J.A. (2006b) Calcium phosphate cements as bone drug 
delivery systems: A review. J Controlled Release 113, 102-110.  
Hamanishi, C., Kitamoto, K., Tanaka, S., Otsuka, M., Doi, Y. and Kitahashi, T. (1996) A self-
setting TTCP-DCPD apatite cement for release of vancomycin. J Biomed Mater Res Part B: 
Appl Biomater 33, 139-143.  
Hofmann, M., Mohammed, A., Perrie, Y., Gbureck, U. and Barralet, J. (2009) High-strength 
resorbable brushite bone cement with controlled drug-releasing capabilities. Acta Biomater 5, 
43-49.  
Hsu, S.T.D., Breukink, E., Tischenko, E., Lutters, M.A.G., De Kruijff, B., Kaptein, R., Bonvin, 
A.M.J.J. and Van Nuland, N.A.J. (2004) The nisin–lipid II complex reveals a pyrophosphate 
cage that provides a blueprint for novel antibiotics. Nat Struc Molec Biol 11, 963-967.  
Jiranek, W.A., Hanssen, A.D. and Greenwald, A.S. (2006) Antibiotic-loaded bone cement for 
infection prophylaxis in total joint replacement. J Bone Joint Surg 88, 2487-2500.  
Joosten, U., Joist, A., Gosheger, G., Liljenqvist, U., Brandt, B. and Von Eiff, C. (2005) 
Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus 
aureus induced chronic osteomyelitis. Biomater 26, 5251-5258.  
Knoetze, H., Todorov, S. and Dicks, L.M.T. (2008) A class IIa peptide from Enterococcus 
mundtii inhibits bacteria associated with otitis media. Int J Antimicrob Agents 31, 228-234.  
Stellenbosch University  http://scholar.sun.ac.za
113 
 
 
Kramer, N.E., Smid, E.J., Kok, J., Kruijff, B., Kuipers, O.P. and Breukink, E. (2004) Resistance 
of Gram‐positive bacteria to nisin is not determined by Lipid II levels. FEMS Microbiol Lett 239, 
157-161.  
Krishnan, V., Johnson, J.V. and Helfrick, J.F. (1993) Management of maxillofacial infections: a 
review of 50 cases. J Oral Maxillofac Surg 51, 868-873.  
Le Nihouannen, D., Komarova, S.V., Gbureck, U. and Barralet, J.E. (2008) Bioactivity of bone 
resorptive factor loaded on osteoconductive matrices: Stability post-dehydration. Eur J Pharma 
Biopharma 70, 813-818.  
Maher, S. and McClean, S. (2006) Investigation of the cytotoxicity of eukaryotic and prokaryotic 
antimicrobial peptides in intestinal epithelial cells in vitro. Biochem Pharma 71, 1289-1298. 
Maniatis, T., Fritsch, E.F., Sambrook, J. and Cold Spring Harbor Laboratory, eds. (1982) 
Molecular cloning: a laboratory manual. : Cold Spring Harbor Laboratory Cold Spring Harbor, 
NY.  
Naghmouchi, K., Drider, D., Baah, J. And Teather, R. (2010) Nisin A and Polymyxin B as 
Synergistic Inhibitors of Gram-positive and Gram-negative Bacteria. Prob Antmicrob Prot 2, 98-
103. 
Neu, H.C. (1992) The crisis in antibiotic resistance. Sci 257, 1064-1073.  
Otsuka, M., Nakahigashi, Y., Matsuda, Y., Fox, J.L., Higuchi, W.I. and Sugiyama, Y. (1997) A 
novel skeletal drug delivery system using self-setting calcium phosphate cement VIII: The 
relationship between in vitro and in vivo drug release from indomethacin-containing cement. J 
Controlled Release 43, 115-122.  
Parvizi, J., Saleh, K.J., Ragland, P.S., Pour, A.E. and Mont, M.A. (2008) Efficacy of antibiotic-
impregnated cement in total hip replacement. Acta orthopaed 79, 335-341.  
Piper, C., Hill, C., Cotter, P.D. and Ross, R.P. (2010) Bioengineering of a Nisin A-producing 
Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q and Z. 
Microb Biotech, 4, 375-382.  
Stellenbosch University  http://scholar.sun.ac.za
114 
 
 
Ruhe, P., Boerman, O., Russel, F., Spauwen, P., Mikos, A.G. and Jansen, J.A. (2005) Controlled 
release of rhBMP-2 loaded poly (DL-lactic-co-glycolic acid)/calcium phosphate cement 
composites in vivo. J Controlled Release 106, 162-171.  
Schnieders, J., Gbureck, U., Thull, R. and Kissel, T. (2006) Controlled release of gentamicin 
from calcium phosphate-poly (lactic acid-co-glycolic acid) composite bone cement. Biomates 27, 
4239-4249.  
Stallmann, H.P., Faber, C., Bronckers, A.L.J.J., Nieuw Amerongen, A.V. and Wuisman, P.I.J.M. 
(2004) Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11-or gentamicin-
containing calcium phosphate cement. J Antimicrob Chemother 54, 472-476.  
Stewart, P.S. and William Costerton, J. (2001) Antibiotic resistance of bacteria in biofilms. The 
Lancet 358, 135-138.  
Tamimi, F., Torres, J., Bettini, R., Ruggera, F., Rueda, C., López-Ponce, M. and Lopez-
Cabarcos, E. (2008) Doxycycline sustained release from brushite cements for the treatment of 
periodontal diseases. J Biomed Mater Res Part A 85, 707-714.  
Tamimi, F., Torres, J., Lopez-Cabarcos, E., Bassett, D.C., Habibovic, P., Luceron, E. and 
Barralet, J.E. (2009) Minimally invasive maxillofacial vertical bone augmentation using brushite 
based cements. Biomater 30, 208-216.  
Thornes, B., Murray, P. and Bouchier-Hayes, D. (2002) Development of resistant strains of 
Staphylococcus epidermidis on gentamicin-loaded bone cement in vivo. J Bone Joint Surg (Br) 
84, 758-760.  
Van de Belt, H., Neut, D., Schenk, W., Van Horn, J.R., Van der Mei, H.C. and Busscher, H.J. 
(2001) Infection of orthopedic implants and the use of antibiotic-loaded bone cements: A review. 
Acta Orthopaed 72, 557-571.  
Van Staden, A.D., Heunis, T.D.J. and Dicks, L.M.T. (2011) Release of Enterococcus mundtii 
bacteriocin ST4SA from self-setting brushite bone cement. Prob Antimicrob Prot 3, 119-124.  
Walsh, C. (2003) Antibiotics: actions, origins, resistance. Wasington, DC: American Society for 
Microbiology Press.  
Stellenbosch University  http://scholar.sun.ac.za
115 
 
 
Winkowski, K., Bruno, M. and Montville, T.J. (1994) Correlation of bioenergetic parameters 
with cell death in Listeria monocytogenes cells exposed to nisin. Appl Environ Microbiol 60, 
4186-4188.  
Young, A.M., Ng, P.Y.J., Gbureck, U., Nazhat, S.N., Barralet, J.E. and Hofmann, M.P. (2008) 
Characterization of chlorhexidine-releasing, fast-setting, brushite bone cements. Acta Biomater 
4, 1081-1088.  
Zhang, W., Walboomers, X.F. and Jansen, J.A. (2008) The formation of tertiary dentin after pulp 
capping with a calcium phosphate cement, loaded with PLGA microparticles containing TGF-β1. 
J Biomed Mater Res Part A 85, 439-444.  
Zimmerli, W. (2006) Prosthetic-joint-associated infections. Best Prac Res Clin Rheumatol 20, 
1045-1063.  
  
Stellenbosch University  http://scholar.sun.ac.za
116 
 
 
Figure 1A 
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Figure 1B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Scanning electron microscopy (SEM) images and X-ray diffraction (XRD) patterns of 
(A) control brushite bone cement samples (without nisin F) and (B) nisin F-loaded (5∙0%, w/w) 
brushite bone cement samples.  SEM images were captured at 5000 times magnification.  The 
scale bar indicates 2 µm.  Main brushite peaks (*) and peaks observed for β-TCP (•) and MCPM 
(+) are indicated in the XRD graphs. 
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Figure 2 Release of nisin F from brushite bone cement over three days. S. aureus Xen 36 served 
as sensitive strain.  Nisin F 6,400 AU ( ); Nisin F 3,200 AU ( ); Nisin 1,280 AU ( ). * p < 
0.05; nisin F 6,400 AU vs. 3,200 AU (Student‟s t-test). 
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Figure 3 Bacterial cells were dyed and added to bone cement samples containing different 
bacteriocin concentrations; 6,400 AU (G-L), 3,200 AU (M-R) and 1,280 AU (S-X).  Green cells 
indicate all bacteria in the sample and red cells indicate membrane compromised bacterial cells.  
Images were taken at 5∙0 min, 30 min and 60 min.  Images A-F are control bone cement samples 
containing no bacteriocin. Images AB-WX indicate overlaid images (green and red 
fluorescence), membrane compromised cells are seen as yellow. Scale bar represents 0∙02 mm. 
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Figure 4 Cumulative release of nisin F (5.0%, w/w) from brushite cement, expressed as a 
percentage of the original protein content. 
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Figure 5 Bioluminescent images are represented on a colour scale overlaid on top of a greyscale 
image.  A: Group 1 (untreated and uninfected), group 2 (treated and uninfected), group 3 
(untreated and infected), group 4 (treated and infected).  B: Representative images of 
implantation sites after a seven day trial. C: Graph represents average radiance of S. aureus Xen 
36. Group 1 ( ), group 2 ( ), group 3 ( ) and group 4 ( ). * p < 0.001 group 3 vs. group 4 
(Student‟s t-test).  
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General Discussion and Conclusions 
Characterization of brushite composites 
Incorporation of peptide ST4SA, ST4SA-PLGA particles, or nisin F into cement did not result in 
substantial changes in the cement setting reaction or crystal structure. Incorporation of other 
therapeutic agents have also shown little effect on setting reaction or crystal entanglement 
(Bohner et al. 1997; Schnieders et al. 2006; Young et al. 2008; Fullan a et al. 2010), rendering 
the results of this study not that surprising. The type and concentration of the drug plays an 
important role, for example addition of high gentamicin results in longer setting times whereas 
high chlorhexidine concentrations results in faster setting times (Bohner et al. 1997; Young et al. 
2008). The effects bacteriocins may have on cement setting and structural characteristics need to 
be studied. In addition to these tests, mechanical tests should also be performed on the 
bacteriocin-cement composites.  
Release of bacteriocins from brushite composites 
Several therapeutic agents have been incorporated into calcium phosphate cements (CPC), 
including several antibiotics, growth factors and proteins (Otsuka et al. 1994; Hamanishi et al. 
1996; Bohner et al. 1997; Otsuka et al. 1997; Young et al. 2008; De la Riva et al. 2009). The 
release of these substances from a cement matrix is dependent on several factors, e.g. drug 
solubility, drug cement interaction and porosity of the cement (Bohner et al. 1997; Young et al. 
2008; Hofmann et al. 2009). However, the general trend is a high burst release within the first 24 
h, followed by a steady release, resulting in partial or complete release of the incorporated 
substance. Incorporation of peptide ST4SA or nisin F resulted in a high burst release, followed 
by a steady release. The release trend was, however, slightly more rapid than reported for other 
drugs. Release kinetics can be changed by altering porosity of the cement or by incorporating 
polymeric particles associated with the desired substance (Schnieders et al. 2006; Hofmann et al. 
2009; Fullana et al. 2010).  
Several researchers have reported a decrease in burst release when incorporating therapeutic 
agents into polymeric particles (Schnieders et al. 2006; Basarkar et al. 2007; Fullana et al. 2010; 
Santander-Ortega et al. 2010). Schnieders et al. (2006) reported a significant difference; not only 
in burst release, but total release when gentamicin-PLGA microspheres were incorporated into 
cement. A similar result was seen in the current study when incorporating peptide ST4SA-
PLGA-associated particles into brushite cement. The burst release was significantly reduced, 
compared to microparticles and normal peptide ST4SA cement. Because bacteriocins are active 
at low concentrations against sensitive bacteria, they can be released at low concentrations 
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(Morgan et al. 2005; Nissen-Meyer et al. 2009). This was seen in a study where nisin was 
incorporated into poly (L, lactic acid) particles and released over a period of 40 days, still in an 
active form able to inhibit the target organism. Less than 35% of the nisin was released over the 
40 day trail, illustrating the antimicrobial potency of the peptide (Salmaso et al. 2004). From 
these results, it seems as if the release of bacteriocins at low concentrations, above the minimum 
inhibitory concentration, is sufficient to control bacterial growth. Protection of peptide ST4SA in 
PLGA has not been studied.  This may provide valuable information on the use of microparticles 
to protect bacteriocins from harsh environments. The effect of electrospraying on the activity of 
peptide ST4SA must also be investigated. 
Prevention of S. aureus infection with nisin F brushite composites 
The possible use of bacteriocins as an alternative antimicrobial therapy (AAT) relies on 
extensive research; not only on in vtiro characterization and in vivo properties of the peptides, 
but also on the applications. In vitro research into the possible application of bacteriocins as an 
AAT has been investigated by some researchers (Joerger 2003; Gillor et al. 2005; Knoetze et al. 
2008; Piper et al. 2010). However, it is important to test and confirm the in vitro results in vivo.  
Certain characteristics in complex in vivo situations cannot be simulated in vitro. Research has 
focused on the in vivo efficacy of several bacteriocins (Ingham et al. 2003; Ghiselli et al. 2004; 
Damasko et al. 2005; De Kwaadsteniet et al. 2009; Brand et al. 2010; De Kwaadsteniet et al. 
2010). For this reason, nisin F brushite composites were tested for their in vivo efficacy. Most 
antibiotic-loaded bone cements are used on a prophylactic basis and are not used to treat 
infections, except in certain implant revision cases (Hanssen 2004; Jiranek et al. 2006; Parvizi et 
al. 2008). Therefore, the model used in this study was based on nisin F brushite cement as a 
prophylactic for the prevention of S. aureus infection. The bacterial concentration used to infect 
the subcutaneous pockets, created for implant insertion, was high enough to form an established 
infection that lasted for seven days (Bernthal et al. 2010). The nisin F-loaded cement samples 
prevented the growth of S. aureus over the seven day period. The lantibiotic most likely killed 
the bacteria within the first few minutes of contact, resulting in insufficient viable cells being 
available to sustain the infection. In other in vivo studies with bacteriocins it has been reported 
that the bacteriocins are only able to inhibit bacterial infection for a short time period (Ingham et 
al. 2003; Brand et al. 2010). However, in some cases bacteriocins were more effective in 
preventing infection, especially when associated with medical devices (Bower et al. 2002; 
Ghiselli et al. 2004). When a lower concentration of nisin F-loaded cement was used (i.e. 2∙5%), 
infection could not be controlled, suggesting that the inhibition is dose dependent (Appendix 
A2). Similar findings have been reported by Otsuka et al. (1997) and Bernthal et al. (2010). If 
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purified nisin F is used, a lower concentration may be necessary to obtain the same result. 
Further research must also be performed on the stability of nisin F in vivo.  
Conclusion 
The in vitro results of the current study showed that bacteriocins incorporated into brushite 
cement did not significantly alter the characteristics of the matix and that the peptides were 
released in an active form. The incorporation of ST4SA-associated PLGA particles resulted in a 
delayed release profile with a decreased burst release. Finally it was shown that nisin F-loaded 
brushite cement controlled S. aureus infection in mice. Bacteriocins may thus be a possible 
alternative to antibiotics incorporated into bone cement.  Further research is needed to support 
the findings obtained in this study. 
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STELLENBOSCH UNIVERSITY 
Addendum A1 
Incorporation of bacteriocin associated PEO: 
PDLLA blend nanoparticles into self setting 
brushite bone cements* 
 
 
 
  
*The addendum is supplementary to chapter 4: Incorporation of bacteriocin associated 
Poly (D, L-lactide-co-glycolide) particles into self setting brushite bone cements.  
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Incorporation of bacteriocin associated PEO: PDLLA blend nanoparticles into self setting 
brushite bone cements 
Aims: The aim of the study was to investigate the incorporation of peptide ST4SA associated 
Poly (ethylene oxide); PEO: poly (D, L-lactide); PDLLA blend nanoparticles (produced by 
electrospraying) into brushite cement.  
Methods and Results: Peptide ST4SA was isolated from Enterococcus mundtii ST4SA and 
concentrated using ammonium sulfate precipitation, dialysis and freeze-drying. Listeria 
monocytogenes EGDe was used as sensitive strain.  
Bacteriocin-associated particles (BP) were produced using an electrospraying method. Three 
2∙0% (wt/vol) blends of PEO: PDLLA were prepared, namely 70:30, 50:50 and 30:70. The 
polymer blends were dissolved in DMF containing bacteriocin. A setup using a sterile tapered 
glass tube and high voltage supply was used for the production of particles. A constant potential 
difference of 15 kV was applied to polymer solution and -5 kV to the collector (1∙33 kV/cm).  
Brushite cement was prepared by mixing equimolar concentrations of β-tricalcium phosphate 
and monocalcium phosphate monohydrate. Different BP blends were added at 10% (w/w) and 
ST4SA at 5∙0% w/w to brushite cement and moulded into cylinders. Release of BP and brushite-
BP composites were determined by using BCA protein assays (Fig. 3 and 6). BP were 
characterized using SEM analysis (Fig. 1 and 2), cement composites were characterized using 
XRD and SEM analysis (Fig. 4 and 5),  
Electrosprayed BP had sizes ranging from 161∙443 nm to 800 nm with an average of 783∙74 nm 
(±62∙4) for the PEO 50: PDLLA 50 blends. Sizes ranging from 173∙5 nm to 1973∙4 nm with an 
average of 499∙7 nm (±173∙5) for the PEO 70: PDLLA 30 blends. Sizes ranging from 222∙2 nm 
to 2234∙2 nm with an average of 562∙3 nm (±273∙7) for the PEO 30: PDLLA 70 blends. Most of 
the bacteriocin was release within the first 4 h for all blends. The PEO 50: PDLLA 50 BP-
cement composite differed statistically (p<0∙05) with the control group at 2 and 4 hours. Cement 
composite containing the PEO 30: PDLLA 70 blend differed statistically (p<0∙05) with the 
ST4SA-loaded group at 2, 4 and 6 h. Bacteriocin used for BP production had a protein 
concentration of 10mg mL
-1 
< [protein] < 20mg mL
-1
 and antimicrobial activity of 102400 AU 
mL
-1
. Particle associated bacteriocin retained activity upon release from the particles and BP-
composites (Fig. 7). 
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Conclusions: Peptide ST4SA was successfully associated with PEO: PDLLA blend particles and 
was released in its active form, from BP and brushite-BP composites. Incorporation of PEO 50: 
PDLLA 50 and PEO 30: PDLLA 70 BP to brushite cement resulted in statistically different 
release profiles at certain time points. 
Significance: The current study showed that it is possible to associate a class II bacteriocin with 
PEO: PDLLA blends using an electrospraying method. In addition to this the particles were also 
incorporated into brushite cement. 
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Figure 1 SEM images of blend BP, Scale bar represents 2 µm, image captured at 5000 times 
magnification. Images represent blend BP PEO 70: PDLLA 30 (A), PEO 50: PDLLA 50 (B) and 
PEO 30: PDLLA 70 (C). 
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Figure 2 Graph represents size distribution of blend BP according to analysis of SEM images 
with SEM Image studio. Bars represent blend BP PEO 70: PDLLA 30 ( ), PEO 50: PDLLA 50 
( ) and PEO 30: PDLLA 70 ( ). 
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Figure 3 Cumulative release of peptide ST4SA from PEO 70: PDLLA 30 ( ), PEO 50: 
PDLLA 50 ( ) and PEO 30: PDLLA 70 ( ) blend BP. 
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Figure 4 SEM images of brushite cement samples without BP (A), ST4SA-loaded (5∙0% 
w/w; B) and cement samples containing 10% w/w PEO 50: PDLLA 50 blend BP (C).  Scale 
bar represents 1 µm, image captured at 5000 times magnification. 
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Figure 5 XRD patterns of unloaded (control) composites, ST4SA composites (protein), PEO 70: 
PDLLA 30 (70:30), PEO 50: PDLLA 50 (50:50) and PEO 30: PDLLA 70 (30:70) blend BP 
composites. Red lines indicate main brushite peaks (ICDD 00-009-0077) 
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Figure 6 Cumulative release of peptide ST4SA from ST4SA composites ( ) PEO 70: 
PDLLA 30 ( ), PEO 50: PDLLA 50 ( ) and PEO 30: PDLLA 70 ( ) blend BP 
composites, expressed as percentage of original protein content. 
  
Stellenbosch University  http://scholar.sun.ac.za
138 
 
 
 
Figure 7 Antimicrobial activity of BP and BP blend composites on soft agar seeded with 1% L. 
monocytogenes EGD-e. Images of PEO 70: PDLLA 30 (A), PEO 30: PDLLA 70 (B) and PEO 
50: PDLLA 50 (C) blends are shown. Zones numbered 1 indicate particles placed on plate and 2 
positive ST4SA control. 
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STELLENBOSCH UNIVERSITY 
Addendum A2 
In vivo evaluation of brushite cement loaded with 
2∙5% and 5∙0% nisin F as a method to prevent the 
growth of Staphylococcus aureus* 
 
 
 
  
*The addendum is supplementary to the in vivo section of chapter 5: Nisin F-loaded 
brushite bone cement prevented the growth of Staphylococcus aureus in vivo. 
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In vivo evaluation of brushite cement loaded with 2
.
5% and 5
.
0% nisin F as a method to 
prevent the growth of Staphylococcus aureus 
Aims: The aim of the study was to determine the optimal concentration of nisin F needed to 
prevent infection with S. aureus Xen 36.  
Methods and Results: Brushite cement was prepared by mixing equimolar concentrations of β-
tricalcium phosphate and monocalcium phosphate monohydrate. Nisin F was added at 5.0% and 
2.5% (w/w), respectively, to brushite cement and moulded into cylinders. Nisin F-loaded or 
unloaded cement was implanted into a subcutaneous pocket on the back of mice (n=9) and then 
infected with a bioluminescent S. aureus strain (Xen 36). Infection was monitored for 6 days, 
using an in vivo imaging system (IVIS; Fig. 1A and B). After the 6 day trial implants were 
removed and vortexed in 1 ml sterile saline. Samples were diluted and plated out onto BHI agar 
containing 200 µg ml
-1 
kanamycin (Fig. 2 A and B). Mice implanted with samples containing no 
nisin F showed bioluminescence throughout the 6 day trial period. Viable cells were also isolated 
from removed implants. No bioluminescent signals could be detected for infected mice 
implanted with 5∙0% and 2∙5% w/w nisin F containing samples. Nisin F containing 5.0% w/w 
prevented S. aureus infection for 6 days and no viable cells were isolated from the implants. 
Viable bacteria were isolated from implants containing 2∙5% w/w nisin F.  
Conclusions: Nisin F-loaded (5∙0% w/w) brushite cement successfully prevented in vivo growth 
of S. aureus. However, results suggest that samples containing 2∙5% w/w nisin F was able to 
suppress bioluminescence but unable to completely eradicate bacteria. 
Significance and Impact of the Study: A correlation must be found between bioluminescence 
and bacterial load (from traditional plating techniques) when examining different therapeutic 
concentrations of a drug. This will help determine the lower limit of bioluminescence that can be 
detected from the bacteria used. It is also important to confirm the absence of infection after in 
vivo bioluminescent trails using traditional plating techniques. This was done in chapter 5 as well 
as in the current study and was found to be useful in determining the optimal concentration for 
total prevention and not just suppression of bacterial infection. However these are preliminary 
results and further investigation is needed to determine optimal concentration. 
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Figure 1 Bioluminescent images are represented on a colour scale overlaid on top of a greyscale 
image.  A: Group 1 (untreated and infected), group 2 (treated with 2.5% nisin loaded cement and 
infected) and group 3 (treated with 5.0% nisin loaded cement and infected). Graph represents 
average radiance of S. aureus Xen 36. Group 1 ( ), group 2 ( ) and group 3 ( ). 
* p < 0.001 group 3 vs. group 4 (Student‟s t-test).  
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Day 0       Day 1         Day 2       Day 4         Day 6 
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Figure 2 Undiluted suspensions from removed implants plated out onto BHI (200 µg mL
-1
 
kanamycin). Images indicate samples plated out from cement loaded with 2.5% (A) and 5.0% 
(B) nisin F, respectively. 
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